Protocols & Literature

Consensus DVH planning goals for breast, head and neck, liver, lung, prostate and rectal cancer, built from VA/ASTRO quality-measure work and approved by modified Delphi vote. Tables are also published as Appendix E3 on astro.org. DoseLab's prostate 70 Gy / 28 fx column quotes Table 21.

Publication / protocol

Pract Radiat Oncol. 2026;16(3):294–317

Year

2026

Version

Pending verification

Disease sites

Prostate, Breast, Lung, Head & Neck, GI

Fractionation context

Common conventional, moderately hypofractionated and ultrahypofractionated schedules

Last reviewed by DoseLab

2026-10-14

Endorsed eviQ protocol for early-stage glottic larynx cancer treated with radiotherapy alone. Its target volumes cover the larynx only, without elective nodes, and it notes the effect of swallowing on larynx position.

Publication / protocol

eviQ Radiation Oncology protocol 584

Year

2026

Version

v.5 — last reviewed 30 April 2026; review due 30 June 2030

Disease sites

Head & Neck

Fractionation context

Tis–T1: 63 Gy / 28 fx or 60 Gy / 25 fx; T2: 66–70 Gy / 33–35 fx, 65.25 Gy / 29 fx or 64.8 Gy / 27 fx

Last reviewed by DoseLab

2026-09-24

Endorsed eviQ protocol for definitive radiotherapy, with or without concurrent chemotherapy, for glottic, supraglottic and hypopharyngeal squamous cell carcinoma. Early (T1–T2 N0) glottic cancer without adverse features is covered by a separate protocol.

Publication / protocol

eviQ Radiation Oncology protocol 4356

Year

2026

Version

v.2 — last reviewed 30 April 2026; review due 30 June 2030

Disease sites

Head & Neck

Fractionation context

70 Gy / 35 fx SIB (63 and 56 Gy dose levels); may be accelerated to 6 fractions per week

Last reviewed by DoseLab

2026-09-24

Endorsed eviQ protocol for definitive chemoradiation of nasopharyngeal carcinoma (T2 or higher, any N). It summarizes the 2025 primary and nodal target delineation guidelines and notes where the 2024 international guideline differs. Separate eviQ protocols cover early-stage disease and chemoradiation after induction chemotherapy.

Publication / protocol

eviQ Radiation Oncology protocol 621

Year

2026

Version

v.6 — last reviewed 30 April 2026; review due 30 June 2030

Disease sites

Head & Neck

Fractionation context

70 Gy / 35 fx SIB (60 and 50 Gy dose levels); alternatives in 33–35 fx

Last reviewed by DoseLab

2026-09-24

Endorsed eviQ protocol for definitive radiotherapy of oropharyngeal squamous cell carcinoma, with or without concurrent chemotherapy. It replaces the earlier separate radiotherapy-alone (740) and chemoradiation (3362) protocols. DoseLab's head and neck constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each. The same organ table appears in eviQ's oral cavity, larynx/hypopharynx, early glottic, nasopharynx and post-operative head and neck protocols.

Publication / protocol

eviQ Radiation Oncology protocol 5049

Year

2026

Version

v.1 — first approved 30 April 2026; review due 30 June 2030

Disease sites

Head & Neck

Fractionation context

70 Gy / 35 fx SIB (63 and 56 Gy dose levels); accelerated 6 fractions per week option

Last reviewed by DoseLab

2026-09-24

Endorsed eviQ protocol for adjuvant radiotherapy after resection of squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx. It covers the risk features that prompt post-operative treatment, the added very-high-dose level for positive margins and extracapsular extension, and timing after surgery.

Publication / protocol

eviQ Radiation Oncology protocol 3390

Year

2026

Version

v.4 — last reviewed 30 April 2026; review due 30 June 2030

Disease sites

Head & Neck

Fractionation context

60 Gy / 30 fx with a 63 Gy high-risk level, or 62–66 Gy / 33 fx; SIB

Last reviewed by DoseLab

2026-09-24

Endorsed eviQ protocol for hippocampal-avoidance whole-brain radiotherapy (HA-WBRT) of brain metastases, 30 Gy in 10 fractions with IMRT or VMAT. Its organ table gives the hippocampal limits from RTOG 0933 and a lens goal; DoseLab's hippocampal avoidance table quotes the NRG CC001 protocol directly and uses eviQ for the lens.

Publication / protocol

eviQ Radiation Oncology protocol 3882

Year

2025

Version

v.4 — last reviewed 21 August 2025; review due 31 December 2029

Disease sites

CNS / Brain

Fractionation context

30 Gy / 10 fx

Last reviewed by DoseLab

2026-09-25

Endorsed eviQ protocol for stereotactic radiosurgery of intact brain metastases. It gives single-fraction, 3-fraction and 5-fraction dose options by lesion size, and an organs-at-risk table with a separate column for each fraction count, each value credited to its primary source (HyTEC, the UK SABR consensus, Timmerman 2022 and others). DoseLab's SRS constraint table reproduces selected values from it. A companion protocol (eviQ 3572) covers post-operative cavity SRS. Check the live page for the current version.

Publication / protocol

eviQ Radiation Oncology protocol 3253

Year

2025

Version

v.5 — last reviewed 21 August 2025; review due 31 December 2029

Disease sites

CNS / Brain

Fractionation context

SRS: 15–24 Gy / 1 fx, 24–30 Gy / 3 fx, 25–35 Gy / 5 fx

Last reviewed by DoseLab

2026-09-25

Endorsed eviQ protocol for palliative whole-brain radiotherapy, 30 Gy in 10 fractions or 20 Gy in 5 fractions with 2D or 3D conformal fields. Its organ table lists the lens and parotids. DoseLab's whole brain table reproduces those two rows.

Publication / protocol

eviQ Radiation Oncology protocol 1251

Year

2025

Version

v.5 — last reviewed 21 August 2025; review due 31 December 2029

Disease sites

CNS / Brain

Fractionation context

30 Gy / 10 fx or 20 Gy / 5 fx

Last reviewed by DoseLab

2026-09-25

The 2025 update of the DAHANCA radiotherapy quality-assurance guidelines, with new chapters on planning complex targets and hypofractionation. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiother Oncol. 2025;210:111028

Year

2025

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Endorsed eviQ protocol for stereotactic treatment of liver metastases in three or five fractions (three preferred when organ limits allow). Its organ table gives a separate column for each fraction count. Patients with cirrhosis are treated as for hepatocellular carcinoma under the companion primary-liver protocol.

Publication / protocol

eviQ Radiation Oncology protocol 4026

Year

2025

Version

v.4 — last reviewed 28 October 2025; review due 30 June 2028

Disease sites

GI

Fractionation context

42–54 Gy / 3 fx or 40–60 Gy / 5 fx

Last reviewed by DoseLab

2026-09-29

Endorsed eviQ protocol for stereotactic treatment of primary liver cancer (hepatocellular carcinoma or intrahepatic cholangiocarcinoma) in five fractions. It covers motion management (breath hold, free breathing with 4DCT, compression or gating), triple-phase contrast CT, fiducials (including lipiodol and surgical clips), contrast-enhanced MRI and rigid co-registration of MRI, PET and CT in the region of the liver. Its organ table draws on the LARK (TROG 17.03) trial protocol and the UK 2022 SABR consensus.

Publication / protocol

eviQ Radiation Oncology protocol 4024

Year

2025

Version

v.4 — last reviewed 28 October 2025; review due 30 June 2028

Disease sites

GI

Fractionation context

27.5–50 Gy / 5 fx

Last reviewed by DoseLab

2026-09-29

Randomized trial comparing single-session with 3-fraction radiosurgery for sporadic vestibular schwannoma, with hearing preservation as the aim. eviQ cites it for its cochlear mean-dose goals in brain metastasis SRS. Citation checked against Crossref.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2025;123(1):107–117

Year

2025

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

1 fx vs 3 fx radiosurgery

Last reviewed by DoseLab

Pending verification

International NRG consensus atlas for target volumes in dose-escalated pancreatic cancer radiotherapy. Besides the contouring steps, it gives practical simulation advice: IV contrast for CT-based plans with a triple-phase protocol considered (arterial, pancreatic and portal venous at 25, 40 and 70 seconds), a small oral volume on the table, motion management for more than 5 mm of motion, fiducials, and fusion with diagnostic MRI or PET to aid contouring. It also tabulates suggested organ metrics for its dose-escalated schedules. Citation checked against Europe PMC.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2025;121(4):918–929

Year

2025

Version

Pending verification

Disease sites

GI

Fractionation context

Dose-escalated: 5, 15 and 25 fraction regimens

Last reviewed by DoseLab

2026-09-29

The template NRG Oncology gives investigators for writing the radiation therapy section of an anal cancer trial. Its example text and values are based on RTOG 0529 and the ECOG-ACRIN DECREASE trial (EA2182), and are meant to be edited for each protocol. It covers immobilization (a supine "frog-leg" position is recommended), CT or PET/CT simulation, rigid registration of MRI and PET to the planning CT, standard structure names, dose compliance tables and planning priorities.

Publication / protocol

NRG Oncology protocol template

Year

2025

Version

Version 2, 10 January 2025

Disease sites

GI

Fractionation context

Example: 50.4–54 Gy (primary), 42–45 Gy (elective nodes), 28–30 fx

Last reviewed by DoseLab

2026-09-29

Endorsed eviQ protocol for preoperative chemoradiation of esophageal and gastroesophageal junction cancer: 41.4 Gy in 23 fractions with weekly carboplatin and paclitaxel, the CROSS regimen. It recommends PET/CT to aid tumor delineation and 4DCT especially for gastroesophageal junction tumors, and its lung limits are deliberately more conservative than in the definitive protocol to lower the risk of pulmonary complications after surgery.

Publication / protocol

eviQ Radiation Oncology protocol 1861

Year

2025

Version

v.8 — last reviewed 17 October 2025; review due 31 December 2027

Disease sites

GI

Fractionation context

41.4 Gy / 23 fx

Last reviewed by DoseLab

2026-09-29

A 2025 multi-society guideline for delineating the primary tumor target volumes in nasopharyngeal carcinoma. A companion guideline by the same group covers nodal target volumes. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Lancet Oncol. 2025;26(9):e477–e487

Year

2025

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Endorsed eviQ protocol for pre-operative long-course chemoradiation of rectal adenocarcinoma. It covers simulation (supine or prone on a bellyboard, MRI and PET/CT to aid tumor delineation), IMRT/VMAT with a simultaneous integrated boost or 3D conformal treatment with a sequential boost, target volumes referenced to the international consensus guideline, and an organs-at-risk table. Its bladder and femoral head values are credited to RTOG 0822. DoseLab's rectal table reproduces selected values. Its review was due 30 June 2026, so a newer version may appear.

Publication / protocol

eviQ Radiation Oncology protocol 1863

Year

2025

Version

v.8 — last reviewed 14 June 2024; review due 30 June 2026

Disease sites

GI

Fractionation context

45 Gy / 25 fx elective with a 50 Gy SIB, or 45 Gy / 25 fx + 5.4 Gy / 3 fx sequential boost

Last reviewed by DoseLab

2026-09-29

Endorsed eviQ protocol for definitive chemoradiation of anal cancer with IMRT and a simultaneous integrated boost: 50.4 Gy in 28 fractions for non-bulky disease or 54 Gy in 30 fractions for bulky primary or nodal disease, with elective nodes at a lower dose level. Target volumes follow the AGITG contouring atlas. Its organs-at-risk table states that it is based on RTOG 0529 and QUANTEC. It stresses keeping overall treatment time short and avoiding treatment breaks.

Publication / protocol

eviQ Radiation Oncology protocol 1860

Year

2024

Version

v.8 — last reviewed 14 June 2024; review due 30 June 2027

Disease sites

GI

Fractionation context

50.4 Gy / 28 fx or 54 Gy / 30 fx (SIB), elective nodes 40–45 Gy

Last reviewed by DoseLab

2026-09-29

Endorsed eviQ protocol for short-course radiotherapy of grade 3–4 astrocytoma and glioblastoma in older or less fit patients: 40.05 Gy in 15 fractions, 34 Gy in 10 fractions or 25 Gy in 5 fractions, with or without chemotherapy. Its organ table keeps the brainstem, optic structures, retina and cord below the prescription dose and gives a lens limit. Its review was due 30 June 2026.

Publication / protocol

eviQ Radiation Oncology protocol 410

Year

2024

Version

v.5 — last reviewed 28 March 2024; review due 30 June 2026

Disease sites

CNS / Brain

Fractionation context

40.05 Gy / 15 fx, 34 Gy / 10 fx or 25 Gy / 5 fx

Last reviewed by DoseLab

2026-09-25

Endorsed eviQ protocol for glioblastoma (IDH-wildtype, CNS WHO grade 4): 60 Gy in 30 fractions with IMRT or VMAT and concurrent chemotherapy. Its organs-at-risk table covers the brain, brainstem, optic chiasm and nerves, cochlea, globes, retina, lens, hippocampus, inner ear, lacrimal gland, pituitary and spinal cord, with PRV limits for the brainstem, optic structures and cord. DoseLab's glioma table reproduces selected values with the primary source eviQ credits for each. Its review was due 30 June 2026, so a newer version may appear.

Publication / protocol

eviQ Radiation Oncology protocol 409

Year

2024

Version

v.5 — last reviewed 28 March 2024; review due 30 June 2026

Disease sites

CNS / Brain

Fractionation context

60 Gy / 30 fx

Last reviewed by DoseLab

2026-09-25

Endorsed eviQ protocol for chest wall radiotherapy after mastectomy. DoseLab's post-mastectomy constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each. When nodes are treated, the protocol refers to its nodal irradiation protocol for organ limits.

Publication / protocol

eviQ Radiation Oncology protocol 1925

Year

2024

Version

v.5 — last reviewed 28 March 2024; review due 30 June 2028

Disease sites

Breast

Fractionation context

Chest wall 50 Gy/25 fx, 40.05 Gy/15 fx or 26 Gy/5 fx

Last reviewed by DoseLab

2026-09-23

Endorsed eviQ protocol for regional nodal irradiation (axilla, supraclavicular fossa and internal mammary chain). DoseLab's regional nodal constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each. The review date eviQ lists had passed when DoseLab checked this page — check the live page for the current version.

Publication / protocol

eviQ Radiation Oncology protocol 1924

Year

2024

Version

v.6 — last reviewed 28 March 2024; review due 30 June 2026

Disease sites

Breast

Fractionation context

45–50 Gy/25 fx or 40 Gy/15 fx to regional nodes

Last reviewed by DoseLab

2026-09-23

Endorsed eviQ protocol for adjuvant whole-breast radiotherapy after breast-conserving surgery. DoseLab's whole breast constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each. For SIB and 5-fraction planning, the protocol points to the RTOG 1005, IMPORT HIGH and FAST-Forward trial protocols.

Publication / protocol

eviQ Radiation Oncology protocol 3650

Year

2024

Version

v.6 — last reviewed 28 March 2024; review due 30 June 2028

Disease sites

Breast

Fractionation context

40.05 Gy/15 fx, 42.4 Gy/16 fx or 26 Gy/5 fx; optional boost or SIB

Last reviewed by DoseLab

2026-09-23

Endorsed eviQ protocol for external-beam partial breast irradiation. Its organ goals are all taken from the 2023 ASTRO partial breast guideline and are expressed as a percentage of the prescription, so one set applies to every schedule. DoseLab's partial breast table reproduces selected values.

Publication / protocol

eviQ Radiation Oncology protocol 3658

Year

2024

Version

v.2 — last reviewed 28 March 2024; review due 30 June 2028

Disease sites

Breast

Fractionation context

40.05 Gy/15 fx, 30 Gy/5 fx (alternate days) or 26 Gy/5 fx

Last reviewed by DoseLab

2026-09-23

Randomized trial of androgen deprivation duration with postoperative radiotherapy. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Lancet. 2024;403(10442):2416–2425

Year

2024

Version

Pending verification

Disease sites

Prostate

Fractionation context

Postoperative

Last reviewed by DoseLab

Pending verification

Endorsed eviQ protocol for definitive or neoadjuvant external beam radiotherapy for vulvar cancer, with or without weekly cisplatin. It covers supine frog-leg setup, wiring of scars and clinical mark-up, bolus for superficial disease, MRI and PET/CT for delineation, SIB or sequential-boost dose levels, CTV rules for the vulva, nodes and the subcutaneous mons bridge (referencing the Gaffney 2016 consensus), and the same organ table as its cervix and endometrium protocols. A companion protocol (eviQ 3748) covers post-operative treatment. Its review is due 31 December 2026.

Publication / protocol

eviQ Radiation Oncology protocol 3749

Year

2024

Version

v.2 — last reviewed 24 December 2024; review due 31 December 2026

Disease sites

GYN

Fractionation context

SIB to 60–70 Gy in 30–35 fx, or 45–50.4 Gy / 25–28 fx with a sequential boost

Last reviewed by DoseLab

2026-09-30

The template NRG Oncology gives investigators for writing the radiation therapy section of a cervical cancer trial, covering external beam (photon, MR-linac and proton) and brachytherapy. It describes supine or prone setup, full- and empty-bladder simulation scans fused to build an internal target volume, diagnostic MRI and PET/CT fusion, standard structure names (including Spc_Bowel and BoneMarrow), example prescriptions, HDR point A and volume-directed (CTV_HR) brachytherapy, and per-protocol and variation-acceptable compliance criteria for both the external beam plan and the combined EBRT + brachytherapy dose. Its values are examples meant to be edited for each trial. DoseLab's cervix tables quote its per-protocol levels.

Publication / protocol

NRG Oncology protocol template

Year

2024

Version

Version 1, May 2024

Disease sites

GYN

Fractionation context

45–50.4 Gy / 25–28 fx pelvis ± nodal boost, then HDR, PDR or LDR brachytherapy

Last reviewed by DoseLab

2026-09-30

The NRG Oncology template for the radiation section of a post-operative endometrial cancer trial. It covers supine or prone setup, vaginal apex markers, full- and empty-bladder scans fused to build the vaginal internal target volume, nodal CTV guidance, standard structure names, example prescriptions (45 or 50.4 Gy), example vaginal cuff brachytherapy schedules alone or as a boost, and per-protocol and variation-acceptable organ goals. For cuff brachytherapy it asks for dose points along the cylinder and verification of the dome position rather than volumetric organ limits. Its values are examples meant to be edited for each trial.

Publication / protocol

NRG Oncology protocol template

Year

2024

Version

Version 1, May 2024

Disease sites

GYN

Fractionation context

45 Gy / 25 fx or 50.4 Gy / 28 fx; vaginal cuff HDR alone or as a boost

Last reviewed by DoseLab

2026-09-30

The NRG Oncology template for the radiation section of a vulvar cancer trial. It covers supine frog-leg or straight-leg setup, wires on gross disease and scars, bolus or virtual bolus, diagnostic MRI and PET/CT fusion (ideally in the treatment position), structure names including the anus and bolus, prescriptions for locally advanced and post-operative treatment with an SIB or a sequential boost, and organ goals evaluated on the composite plan. Its values are examples meant to be edited for each trial.

Publication / protocol

NRG Oncology protocol template

Year

2024

Version

Version May 2024

Disease sites

GYN

Fractionation context

45–50.4 Gy / 25–28 fx with a sequential boost, or an SIB to 55–57.5 Gy in 25 fx

Last reviewed by DoseLab

2026-09-30

The NRG Oncology template for the radiation section of a conventionally fractionated lung trial. Its imaging section allows PET/CT or MRI for structure definition but asks that the final contours be confirmed on the planning CT, follows AAPM TG-132 for deformable registration, and notes that PET can help separate tumor from atelectasis. For plan evaluation it defines the prescription as the dose covering 95% of the PTV, with a protocol-specific D99% requirement, and asks that any dose above 105% of the prescription fall within the PTV rather than in normal tissue outside it.

Publication / protocol

NRG Oncology protocol template

Year

2024

Version

Revised 27 August 2024

Disease sites

Lung

Fractionation context

Standard fractionation

Last reviewed by DoseLab

2026-09-30

Endorsed eviQ protocol for definitive chemoradiation of esophageal cancer: 50.4 Gy in 28 fractions or 50 Gy in 25 fractions, based on the INT 0123 trial. Simulation, target volumes and the organ table mirror the preoperative protocol, except that the lung limits follow QUANTEC rather than the tighter preoperative values.

Publication / protocol

eviQ Radiation Oncology protocol 1865

Year

2024

Version

v.7 — last reviewed 14 June 2024; review due 30 June 2028

Disease sites

GI

Fractionation context

50.4 Gy / 28 fx or 50 Gy / 25 fx

Last reviewed by DoseLab

2026-09-29

Endorsed eviQ protocol for conventionally fractionated chemoradiation of unresectable or borderline resectable pancreatic cancer. It recommends breath-hold CT (or 4DCT when breath hold isn't feasible), IV contrast, optional fiducial markers, and PET, CT or MRI to aid tumor delineation — noting that adequate image fusion may be difficult. The target is the gross tumor and involved nodes only. Its organ table covers the bowel, duodenum, stomach, heart, kidneys, liver and spinal cord.

Publication / protocol

eviQ Radiation Oncology protocol 3581

Year

2024

Version

v.4 — last reviewed 14 June 2024; review due 30 June 2028

Disease sites

GI

Fractionation context

50.4–54 Gy / 28–30 fx (unresectable); 45–50.4 Gy / 25–28 fx (borderline resectable)

Last reviewed by DoseLab

2026-09-29

Endorsed eviQ protocol for definitive EBRT of intermediate-risk prostate cancer. DoseLab's definitive prostate constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each.

Publication / protocol

eviQ Radiation Oncology protocol 234

Year

2024

Version

v.7 — last reviewed 7 November 2024; review due 31 December 2026

Disease sites

Prostate

Fractionation context

60 Gy/20 fx or 78–80 Gy/39–40 fx

Last reviewed by DoseLab

2026-09-22

Endorsed eviQ protocol for definitive EBRT to the prostate and pelvic lymph nodes with a simultaneous integrated boost. DoseLab's prostate + pelvic nodes constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each.

Publication / protocol

eviQ Radiation Oncology protocol 3657

Year

2024

Version

v.3 — last reviewed 7 November 2024; review due 31 December 2026

Disease sites

Prostate

Fractionation context

SIB: 60 Gy/20 fx, 68 Gy/25 fx or 78–80 Gy/39–40 fx

Last reviewed by DoseLab

2026-09-22

Endorsed eviQ protocol for prostate SBRT. DoseLab's prostate SBRT constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each.

Publication / protocol

eviQ Radiation Oncology protocol 4140

Year

2024

Version

v.2 — last reviewed 7 November 2024; review due 31 December 2026

Disease sites

Prostate

Fractionation context

36.25 Gy/5 fx to PTV (40 Gy to CTV)

Last reviewed by DoseLab

2026-09-22

Endorsed eviQ protocol for post-prostatectomy (adjuvant or salvage) radiotherapy to the prostate bed. DoseLab's prostate bed constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each.

Publication / protocol

eviQ Radiation Oncology protocol 4487

Year

2024

Version

v.1 — first approved 7 November 2024; review due 31 December 2026

Disease sites

Prostate

Fractionation context

64–66 Gy/32–33 fx or 52.5 Gy/20 fx

Last reviewed by DoseLab

2026-09-22

Endorsed eviQ protocol for pre-operative short-course radiotherapy (25 Gy in 5 fractions) for rectal cancer. It notes that few published protocols give organ limits for short-course IMRT or VMAT, and takes its bowel and bladder values from the Royal College of Radiologists' national rectal IMRT guidance. It also asks for care in sparing the anal canal for tumors 6 cm or more from the anal verge. Its review was due 30 June 2026, so a newer version may appear.

Publication / protocol

eviQ Radiation Oncology protocol 1874

Year

2024

Version

v.7 — last reviewed 14 June 2024; review due 30 June 2026

Disease sites

GI

Fractionation context

25 Gy / 5 fx

Last reviewed by DoseLab

2026-09-29

Results of the UK IMPORT HIGH trial of dose-escalated simultaneous integrated boost radiotherapy. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Lancet. 2023;401(10394):2124–2137

Year

2023

Version

Pending verification

Disease sites

Breast

Fractionation context

Whole breast with simultaneous integrated boost

Last reviewed by DoseLab

Pending verification

ESTRO-EANO guideline for glioblastoma radiotherapy: target volume definition (a single CTV around the resection cavity and residual tumor), dose and fractionation, and planning details. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiother Oncol. 2023;184:109663

Year

2023

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

60 Gy / 30 fx; hypofractionated schedules for older patients

Last reviewed by DoseLab

Pending verification

Endorsed eviQ protocol for oral cavity squamous cell carcinoma treated with radiotherapy instead of surgery — for example when the tumor is unresectable or the patient is medically inoperable. It notes that surgery, with or without post-operative radiotherapy, remains the standard for most oral cavity cancers.

Publication / protocol

eviQ Radiation Oncology protocol 3468

Year

2023

Version

v.3 — last reviewed 8 June 2023; review due 30 June 2027

Disease sites

Head & Neck

Fractionation context

70 Gy / 35 fx SIB (63 and 56 Gy dose levels); 66 Gy / 33 fx for superficial tumors

Last reviewed by DoseLab

2026-09-24

ASTRO clinical practice guideline on partial breast irradiation. eviQ takes all of its partial-breast organ goals from this guideline's planning table. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Pract Radiat Oncol. 2023

Year

2023

Version

Pending verification

Disease sites

Breast

Fractionation context

External-beam PBI schedules

Last reviewed by DoseLab

Pending verification

Endorsed eviQ protocol for definitive conventionally fractionated NSCLC treatment. DoseLab's conventional lung constraint table reproduces its organs-at-risk values and citations. Check the live page for the current version.

Publication / protocol

eviQ Radiation Oncology protocol 1871

Year

2023

Version

v.7 — last reviewed 16 March 2023; review due 30 June 2027

Disease sites

Lung

Fractionation context

60 Gy in 30 fractions

Last reviewed by DoseLab

2026-09-22

Endorsed eviQ protocol for central lung SABR. DoseLab's five-fraction column reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each. Check the live page for the current version.

Publication / protocol

eviQ Radiation Oncology protocol 4018

Year

2023

Version

v.3 — last reviewed 16 March 2023; review due 30 June 2027

Disease sites

Lung

Fractionation context

SBRT: 50 Gy/5 fx, 60 Gy/8 fx

Last reviewed by DoseLab

2026-09-22

Endorsed eviQ protocol for peripheral lung SABR. DoseLab's Lung SBRT constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each. Check the live page for the current version.

Publication / protocol

eviQ Radiation Oncology protocol 3389

Year

2023

Version

v.3 — last reviewed 16 March 2023; review due 30 June 2027

Disease sites

Lung

Fractionation context

SBRT: 30–34 Gy/1 fx, 48 Gy/4 fx, 54 Gy/3 fx

Last reviewed by DoseLab

2026-09-22

Final results of NRG CC001 with more than a year of median follow-up: sustained preservation of cognition and fewer patient-reported neurologic symptoms with hippocampal avoidance. Citation checked against Crossref.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2023;117(3):571–580

Year

2023

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

30 Gy / 10 fx

Last reviewed by DoseLab

Pending verification

An editorial history of the UT Southwestern SABR constraint tables — often called the “Timmerman tables” — covering how they were developed and revised, and their relationship to AAPM TG-101 and NRG/RTOG protocols. Tables 2–11 separate serial tissues (listed with a volume, a volume max and a max point dose) from parallel tissues (listed with a critical volume and a critical-volume dose max). In Tables 2–7 a footnote defines “point” as ≤0.035 cm³; Tables 8–11 add a contouring-instructions column for each structure.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2022;112(1):4–21

Year

2022

Version

Pending verification

Disease sites

Lung, Other, CNS / Brain

Fractionation context

1, 2, 3, 4, 5, 8, 10, 15, 20 and 30 fractions (Tables 2–11)

Last reviewed by DoseLab

2026-09-22

Retrospective study relating LAD dose to cardiac events after breast radiotherapy. Citation as given in a 2025 Radiotherapy and Oncology review of breast dose constraints; not yet checked against the journal.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2022;114:130–139

Year

2022

Version

Pending verification

Disease sites

Breast

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

An open-access multicenter summary of organ-at-risk dose–volume constraints for adults (Table 1) and contouring definitions based on the Global Harmonization Group nomenclature (Table 2). DoseLab uses its large bowel row where eviQ gives no number.

Publication / protocol

Curr Oncol. 2022;29(10):7021–7050

Year

2022

Version

Pending verification

Disease sites

Lung, Prostate, GI, GYN, Head & Neck, CNS / Brain, Breast

Fractionation context

Conventional; SBRT at 1, 3, 5 and 8 fractions

Last reviewed by DoseLab

2026-09-22

Endorsed eviQ protocol for the brachytherapy boost in definitive treatment of cervical cancer. It describes the insertion procedure (anesthesia, examination, Foley catheter, ultrasound-guided applicator placement, packing), CT or MRI planning with the GEC-ESTRO MRI sequences, the GTV, high-risk and intermediate-risk CTVs, the traditional ICRU 38 points, HDR schedules of 6–8 Gy in 3–5 fractions to the HR-CTV, and total EQD2 aims for the target and for bladder, rectum, sigmoid and bowel D2cc, most credited to EMBRACE II and GEC-ESTRO. Its review is due 31 December 2026.

Publication / protocol

eviQ Radiation Oncology protocol 1319

Year

2022

Version

v.5 — last reviewed 16 June 2022; review due 31 December 2026

Disease sites

GYN

Fractionation context

HR-CTV 24–30 Gy in 3–5 HDR fractions (6–8 Gy) after EBRT

Last reviewed by DoseLab

2026-09-30

Endorsed eviQ protocol for definitive external beam radiotherapy for cervical cancer, given with brachytherapy and usually with weekly cisplatin. It covers supine setup with a comfortably full bladder, MRI and PET/CT for delineation, an optional internal target volume from full- and empty-bladder scans, 45 Gy in 25 fractions with a sequential or SIB nodal boost, and an organ table (small bowel, duodenum, rectum, bladder, femoral heads, kidneys, bone marrow and, for extended fields, spinal cord). Several of its organ values are credited to post-operative trials (RTOG 1203, RTOG 0724) and EMBRACE II. Its review is due 31 December 2026.

Publication / protocol

eviQ Radiation Oncology protocol 105

Year

2022

Version

v.8 — last reviewed 16 June 2022; review due 31 December 2026

Disease sites

GYN

Fractionation context

45 Gy / 25 fx pelvis with a sequential or SIB nodal boost

Last reviewed by DoseLab

2026-09-30

Endorsed eviQ protocol for adjuvant pelvic external beam radiotherapy after hysterectomy for endometrial cancer. It covers simulation with a vaginal marker and optional full- and empty-bladder scans, 45–50.4 Gy in 25–28 fractions, an optional vault boost by EBRT or HDR brachytherapy, the vaginal–parametrial and nodal CTVs referenced to the NRG/RTOG post-operative consensus, and an organ table. Its review is due 31 December 2026.

Publication / protocol

eviQ Radiation Oncology protocol 233

Year

2022

Version

v.7 — last reviewed 16 June 2022; review due 31 December 2026

Disease sites

GYN

Fractionation context

45–50.4 Gy / 25–28 fx

Last reviewed by DoseLab

2026-09-30

Endorsed eviQ protocol for vaginal vault brachytherapy after hysterectomy, alone or as a boost after pelvic EBRT. It allows a standard library plan, lists example HDR schedules prescribed at the vaginal surface or at 5 mm depth (taken from the American Brachytherapy Society fractionation compendium), and defines the CTV as the upper half or upper 4 cm of the vagina, whichever is greater. It gives no organ limits for this treatment. Its review is due 31 December 2026.

Publication / protocol

eviQ Radiation Oncology protocol 3660

Year

2022

Version

v.2 — last reviewed 16 June 2022; review due 31 December 2026

Disease sites

GYN

Fractionation context

HDR vaginal cuff alone (e.g. 7 Gy × 3 at 5 mm) or as a boost (e.g. 5 Gy × 2)

Last reviewed by DoseLab

2026-09-30

NCCN guideline for anal cancer. Cited by CORSAIR for large bowel constraints; DoseLab has not read the guideline itself.

Publication / protocol

NCCN Guidelines, Anal Cancer, Version 2.2022

Year

2022

Version

2.2022

Disease sites

GI

Fractionation context

Conventional

Last reviewed by DoseLab

Pending verification

ASTRO clinical practice guideline on radiotherapy for intact and resected brain metastases: when to use SRS, when to consider surgery, and hippocampal avoidance with memantine for patients with a good prognosis who receive whole-brain treatment. Citation checked against Crossref.

Publication / protocol

Pract Radiat Oncol. 2022;12(4):265–282

Year

2022

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

UK consensus on dose–volume constraints for SABR of oligometastases, primary lung cancer and hepatocellular carcinoma. Citation checked against Crossref. DoseLab read the tables in the authors' accepted manuscript (UCL Discovery and White Rose Research Online): Table 6 (intracranial, 1, 3 and 5 fractions) for the brain pages, and Tables 2, 3 and 5 (thoracic, abdominal and spinal) for the liver SBRT page. Each table gives optimal and mandatory limits by fraction count; the liver limits apply to patients with, at worst, Child-Pugh A6 liver disease. The kidney limit is written as a "cold" constraint — at least 200 cc must receive no more than the stated dose.

Publication / protocol

Clin Oncol (R Coll Radiol). 2022;34(5):288–300

Year

2022

Version

Pending verification

Disease sites

Lung, CNS / Brain, GI

Fractionation context

SABR, multiple schedules

Last reviewed by DoseLab

2026-09-29

Delphi consensus recommendations on the use of bolus in post-mastectomy radiotherapy. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Radiother Oncol. 2021;164:115–121

Year

2021

Version

Pending verification

Disease sites

Breast

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Evidence-based guideline from the Chinese Society of Clinical Oncology and ASCO on chemotherapy with definitive radiotherapy for stage II–IVA nasopharyngeal carcinoma. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

J Clin Oncol. 2021;39(7):840–859

Year

2021

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Quality assessment of treatment plans from the randomized DBCG HYPO trial (whole breast, 50 Gy in 25 fractions vs 40 Gy in 15 fractions). It lists the trial's limits for the breast target, ipsilateral lung, heart and LAD (called LADCA), reports compliance, and suggests stricter lung and heart limits for future whole-breast planning. LAD delineation was optional in the trial.

Publication / protocol

Clin Transl Radiat Oncol. 2021;28:118–123

Year

2021

Version

Pending verification

Disease sites

Breast

Fractionation context

Whole breast, 50 Gy/25 fx vs 40 Gy/15 fx

Last reviewed by DoseLab

2026-09-23

A series of organ- and tumor-specific reviews of dose-response data for hypofractionated treatments.

Publication / protocol

Int J Radiat Oncol Biol Phys (series)

Year

2021

Version

Pending verification

Disease sites

Lung, CNS / Brain, Other

Fractionation context

Hypofractionated / SBRT / SRS

Last reviewed by DoseLab

Pending verification

UK guidance recommending that the spleen be contoured whenever it may be irradiated, that the mean splenic dose be reported, and that it be kept below 10 Gy when clinically appropriate. Patients above 10 Gy should be considered at higher risk of late functional hyposplenism, with vaccination and antibiotic prophylaxis discussed.

Publication / protocol

RCR Clinical Oncology publication

Year

2021

Version

November 2021

Disease sites

GI

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-09-29

EMBRACE-I, a prospective multicenter cohort of chemoradiation with MRI-guided adaptive brachytherapy for locally advanced cervical cancer, reporting high local control and the dose–response relationships behind the EMBRACE II planning aims. Citation checked against Europe PMC.

Publication / protocol

Lancet Oncol. 2021;22(4):538–547

Year

2021

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

UK national guidance for rectal IMRT and VMAT. It covers pre-treatment imaging (dedicated rectal MRI, with PET-CT in selected cases), fusing the diagnostic or planning MRI with the planning CT and having the oncologist approve the registration, target volume definitions and an atlas, SIB strategies, beam and arc arrangements, CBCT matching, and organ limits for long-course and short-course treatment with either bowel loops or a bowel cavity. The short-course limits come from single-institution protocols (Glasgow and Leeds). DoseLab read the January 2021 PDF.

Publication / protocol

RCR Clinical Oncology publication

Year

2021

Version

January 2021

Disease sites

GI

Fractionation context

Long-course (45–50.4 Gy / 25–28 fx, SIB options) and short-course (25 Gy / 5 fx)

Last reviewed by DoseLab

2026-09-29

The NRG Oncology template for the radiation section of a brain tumor trial. It strongly encourages MRI for target delineation (contrast T1, T2/FLAIR and a 3D gradient-echo sequence), recommends fusing FDG-PET/CT when available, and asks that the fusion be done by a medical physicist or a dosimetrist under physicist supervision and reviewed by the attending physician.

Publication / protocol

NRG Oncology protocol template

Year

2021

Version

Version 1, 5 August 2021

Disease sites

CNS / Brain

Fractionation context

Conventional fractionation

Last reviewed by DoseLab

2026-09-30

The template NRG Oncology gives investigators for the radiation therapy section of a lower GI (rectal) trial. Its example uses 45 Gy in 25 fractions with a 5.4 Gy sequential boost, or a single-phase simultaneous integrated boost, and recommends rigid registration of MRI and PET with the planning CT. Values in it are examples to be edited for each trial.

Publication / protocol

NRG Oncology protocol template

Year

2021

Version

Version 1, 4 July 2021

Disease sites

GI

Fractionation context

Example: 45 Gy / 25 fx + 5.4 Gy / 3 fx, or a single-phase SIB

Last reviewed by DoseLab

2026-09-29

The template NRG Oncology gives investigators for the radiation therapy section of a pancreatic cancer trial. It asks patients not to eat or drink for at least two hours before simulation and treatment and then drink a consistent volume, allows breath hold or fiducial-based gating or tracking, and recommends rigid registration of MRI and PET with the planning CT.

Publication / protocol

NRG Oncology protocol template

Year

2021

Version

Version 1, 4 July 2021

Disease sites

GI

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-09-29

NRG Oncology/RTOG consensus update on the clinical target volumes for post-operative pelvic IMRT after hysterectomy for endometrial or cervical cancer — vaginal cuff, parametria and the pelvic nodal regions. NRG hosts the atlas images and viewer packages on its gynecologic CIRO page. Citation checked against Europe PMC.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2021;109(2):413–424

Year

2021

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Efficacy results of the POP-RT randomized phase 3 trial. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

J Clin Oncol. 2021;39(11):1234–1242

Year

2021

Version

Pending verification

Disease sites

Prostate

Fractionation context

Prostate only vs whole pelvis

Last reviewed by DoseLab

Pending verification

Analysis of osteoradionecrosis of the jaw after head and neck radiotherapy, including mandible dose–volume factors. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiat Oncol. 2021;16(1):1

Year

2021

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

The HyTEC brain report. From pooled published data it models the risk of radionecrosis after single-fraction and fractionated radiosurgery. For single-fraction SRS of brain metastases, V12 Gy of 5, 10 or more than 15 cm³ (brain including the targets) was linked to about 10%, 15% and 20% risk of symptomatic radionecrosis; for 3 and 5 fractions, V20 Gy or V24 Gy under 20 cm³ was linked to under 10% risk of any necrosis or edema. Numbers read from the PubMed abstract; citation checked against Crossref.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2021;110(1):68–86

Year

2021

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

SRS: 1, 3 and 5 fractions

Last reviewed by DoseLab

2026-09-25

Protocol paper for an Australian and Danish phase 2 trial of liver SBRT with kilovoltage intrafraction monitoring. Its supplementary tables (Additional file 1) give organ constraints for HCC (5 fractions) and for liver metastases (3 and 5 fractions), and liver limits — including an HCC liver-mean limit for each prescription and a minimum volume of liver kept below 15 Gy. The constraints were adapted from existing recommendations and trials including UK CORE, RTOG 1112 and NRG BR001. DoseLab read the supplementary tables.

Publication / protocol

BMC Cancer. 2021;21:494 (with Additional file 1)

Year

2021

Version

Pending verification

Disease sites

GI

Fractionation context

HCC 27.5–50 Gy / 5 fx; metastases 42–54 Gy / 3 fx or 40–60 Gy / 5 fx

Last reviewed by DoseLab

2026-09-29

Practical guidance on visualizing the urethra for prostate planning. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

J Med Radiat Sci. 2021;68(3):282–288

Year

2021

Version

Pending verification

Disease sites

Prostate

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Randomized phase 3 trial comparing adjuvant with early salvage radiotherapy after radical prostatectomy. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Lancet Oncol. 2020;21(10):1331–1340

Year

2020

Version

Pending verification

Disease sites

Prostate

Fractionation context

Postoperative, conventional

Last reviewed by DoseLab

Pending verification

Phase 3 trial of 518 patients with brain metastases randomized to whole-brain radiotherapy with or without hippocampal avoidance, both with memantine. Hippocampal avoidance lowered the risk of cognitive failure with no difference in survival or intracranial control. Citation checked against Crossref.

Publication / protocol

J Clin Oncol. 2020;38(10):1019–1029

Year

2020

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

30 Gy / 10 fx

Last reviewed by DoseLab

Pending verification

Five-year results of the UK FAST-Forward trial, comparing one week of whole-breast or chest wall radiotherapy with three weeks. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Lancet. 2020;395(10237):1613–1626

Year

2020

Version

Pending verification

Disease sites

Breast

Fractionation context

26 Gy/5 fx vs 40 Gy/15 fx

Last reviewed by DoseLab

Pending verification

Late toxicity and quality-of-life results from the randomized POP-RT trial of prostate-only versus whole-pelvic radiotherapy. Citation as given in the eviQ reference list.

Publication / protocol

Radiother Oncol. 2020;145:71–80

Year

2020

Version

Pending verification

Disease sites

Prostate

Fractionation context

25 fractions (prostate-only vs whole pelvis)

Last reviewed by DoseLab

Pending verification

The template NRG Oncology gives investigators for the radiation therapy section of an esophageal trial, using a 50.4 Gy in 28 fraction photon-versus-proton example. It requires motion assessment at simulation, encourages a treatment-position FDG-PET/CT, prefers whole-body PET/CT to help define the volumes, and explains why a maximum-intensity projection should not be used to build the IGTV. Values in it are examples to be edited for each trial.

Publication / protocol

NRG Oncology protocol template

Year

2020

Version

Version 2, 23 April 2020

Disease sites

GI

Fractionation context

Example: 50.4 Gy / 28 fx (photons or protons)

Last reviewed by DoseLab

2026-09-29

NRG Oncology's updated international consensus atlas for elective pelvic lymph node volumes in prostate cancer.

Publication / protocol

Int J Radiat Oncol Biol Phys (published online 2020)

Year

2020

Version

Pending verification

Disease sites

Prostate

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

The proPSMA trial randomized men with high-risk prostate cancer to staging with conventional imaging (CT and bone scan) or PSMA PET/CT before curative surgery or radiotherapy. PSMA PET/CT was more accurate for finding pelvic nodal or distant metastases (92% vs 65%), and the authors concluded it is a suitable replacement for conventional imaging. Citation checked against Europe PMC.

Publication / protocol

Lancet. 2020;395(10231):1208–1216

Year

2020

Version

Pending verification

Disease sites

Prostate

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Randomized phase 3 trial of adjuvant versus observation with early salvage radiotherapy after radical prostatectomy. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Lancet. 2020;396:1413–1421

Year

2020

Version

Pending verification

Disease sites

Prostate

Fractionation context

Postoperative

Last reviewed by DoseLab

Pending verification

Proposes a new homogeneity index. Its introduction lists the indices in use — Dmax/Dp, D5/D95, (D2 − D98)/Dp and the ICRU Report 83 version (D2 − D98)/D50 — notes that lower values of the last two mean a more homogeneous dose, and that each is based on only two or three points of the DVH. Full text read in Europe PMC (PMC6839365).

Publication / protocol

J Appl Clin Med Phys. 2019;20(11):50–56

Year

2019

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-03

An American Brachytherapy Society task group report listing published HDR fractionation schedules for gynecologic brachytherapy — cervix, vaginal cuff alone and as a boost, and others — with their EQD2. Citation checked against Europe PMC.

Publication / protocol

Brachytherapy. 2019;18(4):429–436

Year

2019

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

ESTRO ACROP consensus on post-mastectomy target delineation after implant-based immediate reconstruction. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Radiother Oncol. 2019;137:159–166

Year

2019

Version

Pending verification

Disease sites

Breast

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Review by the DEGRO breast cancer expert panel, ending in recommended limits for the whole heart, the left ventricle and the LAD (Table 3). The authors state that the limits apply to left-sided breast radiotherapy, were developed mainly for whole-breast treatment, may be achievable with conventional and hypofractionated schedules, and may be unavoidably exceeded when the internal mammary nodes are treated. DoseLab read the values from the open-access full text.

Publication / protocol

Strahlenther Onkol. 2019;195(1):1–12 (online 11 October 2018)

Year

2019

Version

Pending verification

Disease sites

Breast

Fractionation context

Conventional and hypofractionated (40–42.5 Gy at 2.5–2.67 Gy) whole-breast RT

Last reviewed by DoseLab

2026-09-23

Randomized phase 3 trial of SBRT versus conventionally or moderately hypofractionated IMRT for localized prostate cancer; acute toxicity report. Later reports give 2-year toxicity and 5-year outcomes.

Publication / protocol

Lancet Oncol. 2019;20(11):1531–1543

Year

2019

Version

Pending verification

Disease sites

Prostate

Fractionation context

SBRT (5 fractions) vs conventional or moderate hypofractionation

Last reviewed by DoseLab

Pending verification

An international expert guideline that ranks targets and organs at risk for nasopharyngeal carcinoma planning and gives ideal and acceptable dose criteria, including D0.03 cc near-maximum doses. A correction was published later in 2019. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2019;105(3):567–580

Year

2019

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Conventional fractionation (about 2 Gy per fraction)

Last reviewed by DoseLab

Pending verification

Australian and New Zealand consensus recommendations for node-positive prostate cancer. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Radiother Oncol. 2019;140:68–75

Year

2019

Version

Pending verification

Disease sites

Prostate

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Phase 3 NRG Oncology trial comparing cetuximab with cisplatin, both given with accelerated IMRT (70 Gy in 35 fractions over 6 weeks), in HPV-positive oropharyngeal cancer. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Lancet. 2019;393(10166):40–50

Year

2019

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

70 Gy / 35 fx, 6 fractions per week

Last reviewed by DoseLab

Pending verification

AAPM task group report on the relative biological effectiveness (RBE) of proton beams. It defines RBE as the ratio of reference-radiation and proton doses producing the same biological effect, notes the ICRU recommendation that RBE-weighted dose be the product of absorbed dose and RBE (unit Gy(RBE)), and summarizes that RBE increases with LET and therefore with depth across a spread-out Bragg peak (on average about 1.1 at entrance, 1.15 at the center, 1.3 at the distal edge and 1.7 in the distal fall-off, for 2 Gy fractions and in vitro cell survival). It concludes that it is premature to adopt a variable RBE model clinically and that a constant RBE of 1.1 should in general be maintained, and lists planning methods commonly used to limit end-of-range RBE and range effects, such as beam angle selection to avoid ranging directly into an adjacent critical structure. Read in Europe PMC (PMC9559855).

Publication / protocol

Med Phys. 2019;46(3):e53–e78

Year

2019

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-07

Seamless phase 1/2 dose-escalation trial of five-fraction SBRT for centrally located early-stage non-small cell lung cancer. The protocol's definition of a “central” tumor is widely referenced.

Publication / protocol

J Clin Oncol. 2019;37(15):1316–1325

Year

2019

Version

Pending verification

Disease sites

Lung

Fractionation context

SBRT (5 fractions)

Last reviewed by DoseLab

Pending verification

Updated consensus on selecting elective nodal levels for definitive radiotherapy of oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, sinonasal and unknown-primary cancers. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiother Oncol. 2019;134:1–9

Year

2019

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

UK SABR Consortium guidance document (2019). Link as given in the eviQ reference list.

Publication / protocol

UK SABR Consortium guidelines, v6.1.0

Year

2019

Version

v6.1.0 (2019)

Disease sites

Lung

Fractionation context

SABR, multiple schedules

Last reviewed by DoseLab

Pending verification

Randomized phase 3 trial comparing SABR with conventional radiotherapy for peripheral stage I NSCLC. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Lancet Oncol. 2019;20(4):494–503

Year

2019

Version

Pending verification

Disease sites

Lung

Fractionation context

SABR: 54 Gy/3 fx or 48 Gy/4 fx vs conventional

Last reviewed by DoseLab

Pending verification

Open-access review. It defines the "five Rs" — repair, re-assortment, repopulation, reoxygenation and radiosensitivity — as the most important biological factors influencing tumor and normal-tissue response to fractionated treatment, and proposes a sixth R, reactivation of the anti-tumor immune response by radiotherapy, discussing how dose and fractionation may affect it. Full text read in Europe PMC (PMC6627091).

Publication / protocol

Cancers (Basel). 2019;11(6):860

Year

2019

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-07

Published protocol of a TROG phase 3 trial of prostate SBRT with androgen deprivation. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

BMJ Open. 2019;9(8):e030731

Year

2019

Version

Pending verification

Disease sites

Prostate

Fractionation context

SBRT, 5 fractions

Last reviewed by DoseLab

Pending verification

Recommendations for standardized naming of targets, organs at risk and dose-volume metrics. Section 9 sets out the DVH-metric nomenclature DoseLab follows: Vx (volume receiving at least dose x), Dx (minimum dose to the hottest sub-volume x), CVx and DCx (the "cold" complements), output units in square brackets (Gy or % of prescription; cc or % of the structure), and an EQD2Gy unit with the α/β written in parentheses — for example D90%(10)[EQD2Gy]. Section 10 asks that DVH metrics say whether a lower-dose PTV is segmented (excludes the higher-dose PTV) or not. Read in the AAPM report PDF.

Publication / protocol

AAPM Report No. 263 (January 2018); also Int J Radiat Oncol Biol Phys. 2018;100(4):1057–1066

Year

2018

Version

Pending verification

Disease sites

Lung, Prostate, GI, Head & Neck, Breast, CNS / Brain, GYN, GU, Sarcoma, Other

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-06

PORTEC-3 compared pelvic radiotherapy alone with chemoradiotherapy followed by adjuvant chemotherapy for high-risk endometrial cancer. Open access. Citation checked against Europe PMC.

Publication / protocol

Lancet Oncol. 2018;19(3):295–309

Year

2018

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Consensus guidelines from multiple international groups for delineating the primary-tumor CTV in definitive radiotherapy of squamous cell carcinoma of the larynx, hypopharynx, oropharynx and oral cavity. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiother Oncol. 2018;126(1):3–24

Year

2018

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

ESTRO ACROP consensus on CT- and MRI-based prostate target delineation. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Radiother Oncol. 2018;127(1):49–61

Year

2018

Version

Pending verification

Disease sites

Prostate

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Retrospective evaluation of SRS/SRT plan-quality metrics for arteriovenous malformations. Its methods section defines each metric: the RTOG conformity index (prescription isodose volume ÷ target volume; ideal 1), RTOG quality of coverage and homogeneity index, and the Paddick conformity index as the product of the under-treatment ratio (share of the target covered) and over-treatment ratio (share of the prescription isodose volume inside the target), noting that ICRU Report 91 recommends the Paddick conformity and gradient indices for reporting stereotactic plans. Full text read in Europe PMC (PMC6299748); citation checked against Crossref.

Publication / protocol

J Med Phys. 2018;43(4):214–220

Year

2018

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

SRS / SRT

Last reviewed by DoseLab

2026-10-03

The template NRG Oncology gives investigators for the radiation therapy section of a liver SBRT trial, based on NRG GI-003. It strongly recommends implanted fiducials, allows several motion-management techniques, and describes the multiphase contrast CT used for hepatocellular carcinoma: non-contrast, arterial phase (hypervascular tumor), portal venous phase (vascular thrombus) and delayed phase (washout). Contrast-enhanced MRI is recommended when contrast CT can't be done.

Publication / protocol

NRG Oncology protocol template (based on NRG GI-003)

Year

2018

Version

Version 2, 7 May 2018

Disease sites

GI

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-09-29

NRG Oncology/RTOG 1203 (TIME-C) randomized women receiving post-operative pelvic radiation for endometrial or cervical cancer to IMRT or standard 4-field radiotherapy. IMRT reduced patient-reported bowel and urinary toxicity during treatment. Citation checked against Europe PMC.

Publication / protocol

J Clin Oncol. 2018;36(24):2538–2544

Year

2018

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Review of proton RBE. It explains that proton prescriptions and organ constraints are based on physical dose multiplied by a generic constant RBE of 1.1, derived from early in vivo measurements; that RBE varies with LET, dose, biological endpoint and tissue radiosensitivity; and gives typical dose-averaged LET values across a spread-out Bragg peak, rising from about 0–3 keV/µm up to the center to 9–15 keV/µm in the dose fall-off, with the rise in LET and RBE extending the biologically effective range by 1 to 2 mm. Read in Europe PMC (PMC6200410).

Publication / protocol

Int J Part Ther. 2018;5(1):2–14

Year

2018

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-07

European Particle Therapy Network consensus on dose constraints for brain and skull-base organs at risk in conventionally fractionated treatment, written in EQD2 with the endpoint behind each limit. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiother Oncol. 2018;128(1):26–36

Year

2018

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

Conventional fractionation (EQD2)

Last reviewed by DoseLab

Pending verification

Systematic review of 64 clinical studies reporting α, β and α/β for human tumors. It found large heterogeneity within and between studies; estimates for prostate and breast tumors generally indicated high fractionation sensitivity, those for head & neck, cervix, bladder and liver tumors low sensitivity, and others were mixed. It notes that whether the LQ model holds at large fraction sizes is debated, and recommends choosing parameters by site, histology and model and exploring a range of values. Full text read in Europe PMC (PMC5956964).

Publication / protocol

Radiat Oncol. 2018;13(1):96

Year

2018

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-06

The overview of the EMBRACE II study of image-guided IMRT with chemotherapy followed by MRI-based adaptive brachytherapy for locally advanced cervical cancer. It sets out the study's external beam dose constraints (hard and soft, with separate bowel limits when the para-aortic nodes are treated), the brachytherapy planning aims and limits for the high-risk CTV, GTV, point A, bladder, rectum, sigmoid and bowel in total EQD2, and the vaginal dose points. Open access.

Publication / protocol

Clin Transl Radiat Oncol. 2018;9:48–60

Year

2018

Version

Pending verification

Disease sites

GYN

Fractionation context

45 Gy / 25 fx EBRT (nodal SIB) + image-guided brachytherapy; totals in EQD2

Last reviewed by DoseLab

2026-09-30

The European Particle Therapy Network contouring atlas for brain organs at risk on CT and MRI, with anatomical descriptions and boundaries. Citation checked against Crossref.

Publication / protocol

Radiother Oncol. 2018;128(1):37–43

Year

2018

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Pooled analysis of cardiac toxicity after dose-escalated radiotherapy for stage III NSCLC. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

J Clin Oncol. 2017;35(13):1387–1394

Year

2017

Version

Pending verification

Disease sites

Lung

Fractionation context

Conventional (dose-escalation trials)

Last reviewed by DoseLab

Pending verification

Analysis of hepatobiliary toxicity after liver SBRT, using a central hepatobiliary tract structure defined as a 15 mm expansion of the portal vein. Citation checked against Europe PMC; DoseLab has not read the paper.

Publication / protocol

Radiother Oncol. 2017;122(1):130–136

Year

2017

Version

Pending verification

Disease sites

GI

Fractionation context

SBRT

Last reviewed by DoseLab

Pending verification

Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2017;97(5):976–985

Year

2017

Version

Pending verification

Disease sites

Prostate

Fractionation context

Conventional (79.2 Gy)

Last reviewed by DoseLab

Pending verification

Analysis of heart dose as a predictor of overall survival in locally advanced NSCLC. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

J Thorac Oncol. 2017;12(2):293–301

Year

2017

Version

Pending verification

Disease sites

Lung

Fractionation context

Conventional

Last reviewed by DoseLab

Pending verification

ICRU report on prescribing, recording and reporting stereotactic treatments delivered with small photon beams. DoseLab has not read the report itself. Its recommendation of the Paddick conformity index and the Paddick gradient index for reporting stereotactic plans is checked as quoted in the open-access Menon 2018 paper. Citation as given in the DEGRO/DGMP statement on the report (Wilke 2019, Strahlenther Onkol).

Publication / protocol

J ICRU. 2014;14(2):1–160 (published 2017)

Year

2017

Version

Pending verification

Disease sites

Lung, CNS / Brain, Other

Fractionation context

Stereotactic (SRS / SBRT)

Last reviewed by DoseLab

Pending verification

The NRG Oncology template for the radiation section of a breast trial (photon and proton). It keeps CT as the dose-calculation image, allows MR, contrast CT and nuclear medicine images (such as PET) to refine the targets, and asks that the local accuracy of the registration and the retention of the breast shape be verified.

Publication / protocol

NRG Oncology protocol template

Year

2017

Version

Version 1, 8 November 2017 (file updated 4 February 2025)

Disease sites

Breast

Fractionation context

Whole breast ± nodes

Last reviewed by DoseLab

2026-09-30

The NRG CC001 trial protocol (version date 26 September 2017, copy posted on ClinicalTrials.gov for NCT02360215). Arm 1 was standard whole-brain radiotherapy with 3D conformal fields; arm 2 was IMRT-based hippocampal avoidance, both 30 Gy in 10 fractions with memantine. Sections 5.2.4–5.2.8 define the CTV and PTV, the required structures (hippocampi, the hippocampal avoidance region, lenses, optic nerves and chiasm), the normalization, the per-protocol and variation-acceptable limits for the PTV, hippocampi and optic structures, and the planning priority order. DoseLab's hippocampal avoidance table quotes section 5.2.7 directly.

Publication / protocol

Protocol document, NRG-CC001 (ClinicalTrials.gov NCT02360215)

Year

2017

Version

Version date 26 September 2017

Disease sites

CNS / Brain

Fractionation context

30 Gy / 10 fx

Last reviewed by DoseLab

2026-09-25

Five-year results of the UK IMPORT LOW trial comparing partial-breast with whole-breast radiotherapy. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Lancet. 2017;390(10099):1048–1060

Year

2017

Version

Pending verification

Disease sites

Breast

Fractionation context

40 Gy/15 fx partial vs whole breast

Last reviewed by DoseLab

Pending verification

Phase 3 trial (NCCTG N107C/CEC.3) after resection of a brain metastasis: cavity SRS preserved cognition better than whole-brain radiotherapy, with no difference in survival. Citation checked against Crossref.

Publication / protocol

Lancet Oncol. 2017;18(8):1049–1060

Year

2017

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

J Clin Oncol. 2017;35(17):1884–1890

Year

2017

Version

Pending verification

Disease sites

Prostate

Fractionation context

Moderate hypofractionation vs conventional

Last reviewed by DoseLab

Pending verification

Phase 3 trial in patients 65 or older with glioblastoma: 40 Gy in 15 fractions with temozolomide improved survival compared with the same radiotherapy alone. Citation checked against Crossref.

Publication / protocol

N Engl J Med. 2017;376(11):1027–1037

Year

2017

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

40 Gy / 15 fx

Last reviewed by DoseLab

Pending verification

AAPM Task Group 132 report on image registration and fusion in radiotherapy. It reviews rigid and deformable registration, points out that every registration carries an uncertainty that should be understood and communicated, and gives recommendations for commissioning and quality assurance of registration software and for checking individual registrations. Citation checked against Europe PMC.

Publication / protocol

Med Phys. 2017;44(7):e43–e76

Year

2017

Version

Pending verification

Disease sites

GI, CNS / Brain, Head & Neck, Lung, Prostate, Breast, GYN, GU, Sarcoma, Other

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Published protocol of a randomized phase II trial comparing single- and multi-fraction SABR for lung oligometastases. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

BMC Cancer. 2016;16:183

Year

2016

Version

Pending verification

Disease sites

Lung

Fractionation context

SABR: 1 fraction vs 4 fractions

Last reviewed by DoseLab

Pending verification

NRG/RTOG consensus recommendations for contouring and treating vulvar cancer with IMRT: GTV and CTV definitions for the vulva and the inguinofemoral and pelvic nodes, with an appendix defining the nodal regions. NRG hosts example consensus cases as viewer packages. Citation checked against Europe PMC.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2016;95(4):1191–1200

Year

2016

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Randomized phase 3 non-inferiority trial of conventional versus moderately hypofractionated IMRT for localized prostate cancer. A correction to this article was also published.

Publication / protocol

Lancet Oncol. 2016;17(8):1047–1060

Year

2016

Version

Pending verification

Disease sites

Prostate

Fractionation context

Moderate hypofractionation vs conventional

Last reviewed by DoseLab

Pending verification

Phase 3 non-inferiority trial (QUARTZ) in non-small cell lung cancer with brain metastases unsuitable for surgery or SRS: adding whole-brain radiotherapy, 20 Gy in 5 fractions, to supportive care gave little additional benefit. Citation checked against Crossref.

Publication / protocol

Lancet. 2016;388(10055):2004–2014

Year

2016

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

20 Gy / 5 fx

Last reviewed by DoseLab

Pending verification

Phase 3 trial (NCCTG N0574) in patients with 1–3 brain metastases: adding whole-brain radiotherapy to radiosurgery caused more cognitive decline at 3 months without improving survival. Citation checked against Crossref.

Publication / protocol

JAMA. 2016;316(4):401–409

Year

2016

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Lancet Oncol. 2016;17(8):1061–1069

Year

2016

Version

Pending verification

Disease sites

Prostate

Fractionation context

Moderate hypofractionation vs conventional

Last reviewed by DoseLab

Pending verification

International consensus on rectal cancer CTV delineation, defining sub-volumes and their anatomical boundaries — with changes to the lateral nodes and the ischiorectal fossa compared with earlier guidelines — and online atlas cases. Citation checked against Europe PMC.

Publication / protocol

Radiother Oncol. 2016;120(2):195–201

Year

2016

Version

Pending verification

Disease sites

GI

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

The NRG Oncology template for the radiation section of a brain radiosurgery trial. Its example text asks for CT slices of 1.25 mm or less, strongly encourages MRI (contrast T1 and a 3D gradient-echo sequence) for target delineation, recommends fusing FDG-PET/CT when available, and asks that the fusion be done by a medical physicist and reviewed by the attending physician. Its plan-evaluation section defines the conformity index (CI, or R100%) as the prescription isodose volume ÷ PTV volume, R50% as the 50% prescription isodose volume ÷ target volume ("R50% defines dose falloff outside the target"), a heterogeneity index D5% ÷ D95%, and coverage as the PTV volume receiving the prescription dose ÷ PTV volume, and notes that criteria such as the CI should account for target size and treatment technology.

Publication / protocol

NRG Oncology protocol template

Year

2016

Version

Version 1, 13 June 2016

Disease sites

CNS / Brain

Fractionation context

SRS (1 fraction)

Last reviewed by DoseLab

2026-09-30

The NRG Oncology template for the radiation section of a head and neck trial. Its simulation section asks for planning images in the treatment position with slices of 3 mm or less, uses MRI and/or PET to aid delineation (MRI especially near the skull base), asks for the MRI to be taken as close as possible to the treatment position with distortion correction applied, and recommends PET/CT and MRI fusion when IV contrast can't be given.

Publication / protocol

NRG Oncology protocol template

Year

2016

Version

Version 1, 14 October 2016 (updated to cGy, 4 March 2025)

Disease sites

Head & Neck

Fractionation context

Conventional fractionation

Last reviewed by DoseLab

2026-09-30

The template NRG Oncology gives investigators for writing the radiation section of a lung SBRT trial. Its imaging section allows PET/CT or MRI for structure definition, asks that the images be registered accurately to the planning scan (following AAPM TG-132 for deformable registration), notes that PET may be needed to separate tumor from atelectasis or fibrosis, and suggests an extra margin when a fused image is the primary image for the GTV. Its target and planning sections (5.2.4 and 5.2.6–5.2.8) define the plan-quality measures for lung SBRT trials: the prescription as the dose covering 95% of the PTV, a D99% requirement, R100% (prescription isodose volume ÷ PTV), R50% (50% prescription isodose volume ÷ PTV) and D2cm (maximum dose at 2 cm from the PTV in any direction, as a percentage of the prescription), with a table of allowable dose spillage by PTV volume. It describes a 20 mm PTV expansion structure used to control intermediate dose spillage, asks that dose above 105% of prescription be avoided outside the PTV, describes a deliberately heterogeneous dose with the hotspot in the central GTV, defines the maximum dose on a 0.03 cc volume, and ranks planning priorities when target coverage and organ limits conflict.

Publication / protocol

NRG Oncology protocol template

Year

2016

Version

Version 1, 14 November 2016 (file updated 1 March 2022)

Disease sites

Lung

Fractionation context

SBRT (1–5 fractions)

Last reviewed by DoseLab

2026-09-30

NRG Oncology's page for RTOG 0920, a phase 3 trial of post-operative IMRT with or without cetuximab for intermediate-risk resected head and neck cancer. The protocol prescribes 60 Gy in 2 Gy fractions (optional 66 Gy high-risk and 56 Gy at-risk levels) and lists IMRT planning goals for the cord and brainstem planning risk volumes, lips, oral cavity, parotids, pharynx, cervical esophagus, larynx and mandible, with a planning priority order. DoseLab read section 6.5.4 of the version dated 25 January 2016 (copy hosted by the University of Cincinnati) for the oral cavity, lip and cervical esophagus values in the head and neck table.

Publication / protocol

Protocol document, RTOG 0920

Year

2016

Version

Version date 25 January 2016

Disease sites

Head & Neck

Fractionation context

60 Gy / 30 fx post-operative (optional 66 Gy and 56 Gy levels)

Last reviewed by DoseLab

2026-09-24

Open-access review of tumor hypoxia in radiotherapy. It traces the history from the early 1900s to Gray's work in the 1950s, describes chronic (diffusion-limited) and acute (fluctuating blood flow) hypoxia, reviews attempts to modify hypoxia — including nitroimidazole radiosensitizers, where nimorazole in head and neck cancer is the only one incorporated into standard treatment, and only in Denmark — and notes that although OER falls as LET rises, the oxygen effect only disappears at around 500 keV/µm or greater, beyond what can be achieved clinically. Full text read in Europe PMC (PMC4990104).

Publication / protocol

J Radiat Res. 2016;57(Suppl 1):i90–i98

Year

2016

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-07

Open-access modeling paper on the physical basis of the oxygen effect. Its introduction summarizes the oxygen enhancement ratio: relative to anoxia, well-oxygenated tumors respond better by a factor of 2.5–3; half-maximum radiosensitivity occurs around an oxygen partial pressure of 3 mmHg, with maximum OER typically reached above 20 mmHg; and oxygen must be present before irradiation or within microseconds of it. It explains the oxygen fixation hypothesis — that DNA radical damage can usually be repaired, but repair is more difficult or impossible when the radical has reacted with oxygen. Full text read in Europe PMC (PMC4765087). (The journal classes it as a research paper; DoseLab uses it for its introductory summary.)

Publication / protocol

Biomed Phys Eng Express. 2015;1(4):045209

Year

2015

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-07

Randomized phase 2 comparison of a single-fraction and a multi-fraction SBRT schedule for peripheral stage I non-small cell lung cancer. An erratum and a long-term follow-up report were also published.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2015;93(4):757–764

Year

2015

Version

Pending verification

Disease sites

Lung

Fractionation context

SBRT (1 vs 4 fractions)

Last reviewed by DoseLab

Pending verification

Consensus guideline and atlas for pelvic node contouring. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2015;92(4):874–883

Year

2015

Version

Pending verification

Disease sites

Prostate

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Consensus CT delineation guidelines for head and neck organs at risk from eight cooperative groups, with anatomical descriptions and example images. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiother Oncol. 2015;117(1):83–90

Year

2015

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Phase 3 ANZUP trial protocol. Citation as given in the eviQ reference list; eviQ gives no further publication details, so the link is a search.

Publication / protocol

ENZARAD / ANZUP 1303 trial protocol

Year

2015

Version

Pending verification

Disease sites

Prostate

Fractionation context

Conventional

Last reviewed by DoseLab

Pending verification

ESTRO consensus on target volume delineation for elective breast and nodal radiotherapy, with a version 1.1 correction published in 2016. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Radiother Oncol. 2015;114(1):3–10 (version 1.1: 2016;118(1):205–208)

Year

2015

Version

Pending verification

Disease sites

Breast

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Expert-panel contouring guidelines and a CTV atlas for esophageal and gastroesophageal junction IMRT, built from three cases (GEJ, distal and mid-upper esophagus) that the panel contoured on simulation CT with the diagnostic PET/CT alongside. Citation checked against Europe PMC.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2015;92(4):911–920

Year

2015

Version

Pending verification

Disease sites

GI

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Two-year patient-reported outcomes from the CHHiP trial. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Lancet Oncol. 2015;16(16):1605–1616

Year

2015

Version

Pending verification

Disease sites

Prostate

Fractionation context

CHHiP schedules

Last reviewed by DoseLab

Pending verification

Planning study comparing IMRT with 3D-conformal whole-breast radiotherapy and proposing a normal tissue index for plan evaluation. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

J Med Radiat Sci. 2015;62(3):184–191

Year

2015

Version

Pending verification

Disease sites

Breast

Fractionation context

Conventional fractionation

Last reviewed by DoseLab

Pending verification

Results of the EORTC 22922/10925 randomized trial of internal mammary and medial supraclavicular nodal irradiation. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

N Engl J Med. 2015;373(4):317–327

Year

2015

Version

Pending verification

Disease sites

Breast

Fractionation context

With or without internal mammary and medial supraclavicular irradiation

Last reviewed by DoseLab

Pending verification

IAEA randomized trial in elderly and/or frail patients with glioblastoma comparing 25 Gy in 5 fractions with 40 Gy in 15 fractions; survival was similar. Citation checked against Crossref.

Publication / protocol

J Clin Oncol. 2015;33(35):4145–4150

Year

2015

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

25 Gy / 5 fx vs 40 Gy / 15 fx

Last reviewed by DoseLab

Pending verification

Illustrated delineation guidance and dose constraints for brain organs at risk in adults and children. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiother Oncol. 2015;114(2):230–238

Year

2015

Version

Pending verification

Disease sites

Head & Neck, CNS / Brain

Fractionation context

Conventional fractionation

Last reviewed by DoseLab

Pending verification

Results of the NCIC CTG MA.20 randomized trial of whole-breast irradiation with or without regional nodal irradiation. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

N Engl J Med. 2015;373(4):307–316

Year

2015

Version

Pending verification

Disease sites

Breast

Fractionation context

Whole breast with or without regional nodal irradiation

Last reviewed by DoseLab

Pending verification

Randomized two-by-two factorial phase 3 trial of standard- versus high-dose chemoradiation (with or without cetuximab) for stage III non-small cell lung cancer. The high-dose arm did not improve survival.

Publication / protocol

Lancet Oncol. 2015;16(2):187–199

Year

2015

Version

Pending verification

Disease sites

Lung

Fractionation context

Conventional (2 Gy per fraction)

Last reviewed by DoseLab

Pending verification

Randomized trial of 40 Gy in 15 fractions versus 50 Gy in 25 fractions for loco-regional breast radiotherapy. The protocol lists the DBCG organ limits used in the trial (Table 7) and quotes the DBCG guideline LAD maximum of 17 Gy (hypofractionated) and 20 Gy (normofractionated), noting that heart limits were under review because of the benefit of treating the internal mammary nodes — so the trial asked centers to delineate the LAD and report its dose rather than enforce a limit.

Publication / protocol

Trial protocol

Year

2015

Version

Protocol version 1.0, 1 September 2015

Disease sites

Breast

Fractionation context

40 Gy/15 fx vs 50 Gy/25 fx loco-regional

Last reviewed by DoseLab

2026-09-23

NRG/RTOG comparison and consensus for contouring the high-risk CTV on CT and on MRI for cervix brachytherapy, with an interactive atlas of consensus cases hosted by NRG Oncology. Citation checked against Europe PMC.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2014;90(2):320–328

Year

2014

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

DEGRO working-group statement defining SBRT for stage I NSCLC. It lists the motion-management approaches in routine use — free-breathing delivery with the internal target volume concept (described as the most commonly practiced), the mean target position concept or real-time tracking, and delivery in specific breathing phases by gating or breath hold — and names safety margins for critical organs (the PRV concept), repositioning or replanning as ways to avoid organ overdose. Full text read in Europe PMC (PMC3889283).

Publication / protocol

Strahlenther Onkol. 2014;190(1):26–33

Year

2014

Version

Pending verification

Disease sites

Lung

Fractionation context

SBRT

Last reviewed by DoseLab

2026-10-06

The 2013 update of the international consensus on the anatomical boundaries of the neck node levels. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiother Oncol. 2014;110(1):172–181

Year

2014

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Review of 105 patients given para-aortic nodal IMRT for gynecologic cancers. A larger duodenal volume receiving 55 Gy predicted late duodenal toxicity; the authors suggest keeping V55 below 15 cm³. DoseLab read the abstract.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2014;88(2):357–362

Year

2014

Version

Pending verification

Disease sites

GI, GYN

Fractionation context

45–50.4 Gy with boost to 60–66 Gy

Last reviewed by DoseLab

2026-09-29

Review of swallowing dysfunction after head and neck chemoradiotherapy and the dosimetric factors that can reduce it. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Head Neck. 2014;36(2):291–298

Year

2014

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Single-arm phase 2 trial of hippocampal-avoidance whole-brain radiotherapy, 30 Gy in 10 fractions, compared with a historical control; it showed less memory decline at 4 months. Its protocol defined the hippocampal contouring and dose limits later used in NRG CC001. Citation checked against Crossref.

Publication / protocol

J Clin Oncol. 2014;32(34):3810–3816

Year

2014

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

30 Gy / 10 fx

Last reviewed by DoseLab

Pending verification

Compares published contouring methods for the temporal lobe, middle and inner ear, parotid gland and spinal cord in nasopharynx cancer, recommends one method for each (Table 3), and provides a CT–MRI atlas of 33 organs at risk. Citation checked against Crossref; the temporal lobe and spinal cord recommendations were read in the open-access full text.

Publication / protocol

Radiother Oncol. 2014;110:390–397

Year

2014

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

NRG Oncology's page for RTOG 0126, a randomized dose-escalation trial for localized prostate cancer.

Publication / protocol

Protocol, RTOG 0126

Year

2014

Version

Pending verification

Disease sites

Prostate

Fractionation context

Conventional (dose escalation)

Last reviewed by DoseLab

Pending verification

Review of the radiobiology behind SRS and SBRT. It lists the five Rs — repair, repopulation, redistribution, reoxygenation and intrinsic radiosensitivity — notes that the first four were described by Withers and the fifth added by Steel, and explains that redistribution and reoxygenation increase cell kill over a fractionated course while repair and repopulation increase cell survival. It argues that hypoxia is likely to matter more for SRS/SBRT than for conventional fractionation, and concludes that for most tumors the classic 5 Rs and the linear-quadratic model are sufficient, with the excellent clinical results explained by the much larger BEDs delivered (with the likely exception of enhanced antitumor immunity for some tumors). Read in PubMed Central (author manuscript, PMC3893711).

Publication / protocol

Int J Radiat Oncol Biol Phys. 2014;88(2):254–262

Year

2014

Version

Pending verification

Disease sites

Lung, CNS / Brain

Fractionation context

SRS and SBRT (one or a few large fractions) compared with conventional fractionation

Last reviewed by DoseLab

2026-10-07

RTOG consensus guidelines and atlas for delineating upper abdominal normal organs. Citation checked against Europe PMC.

Publication / protocol

Pract Radiat Oncol. 2014;4(2):82–89

Year

2014

Version

Pending verification

Disease sites

GI

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Individual patient data meta-analysis of esophagitis after chemoradiation for NSCLC. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2013;87(4):690–696

Year

2013

Version

Pending verification

Disease sites

Lung

Fractionation context

Conventional chemoradiation

Last reviewed by DoseLab

Pending verification

Population-based case-control study relating mean heart dose to later major coronary events after breast radiotherapy. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

N Engl J Med. 2013;368(11):987–998

Year

2013

Version

Pending verification

Disease sites

Breast

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Phase 2 RTOG trial of dose-painted IMRT with 5-FU and mitomycin-C for anal cancer. It did not meet its primary endpoint, a reduction in grade 2+ acute gastrointestinal and genitourinary toxicity. Its normal-tissue dose goals are quoted by later protocols; DoseLab could not open a readable copy of the protocol document, so values credited to it are shown as the quoting protocol gives them. Citation checked against Europe PMC.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2013;86(1):27–33

Year

2013

Version

Pending verification

Disease sites

GI

Fractionation context

Dose-painted IMRT, 50.4–54 Gy (primary) over 28–30 fx by stage

Last reviewed by DoseLab

Pending verification

Review of serious complications after SABR and strategies to mitigate them. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Clin Oncol (R Coll Radiol). 2013;25(6):378–387

Year

2013

Version

Pending verification

Disease sites

Lung

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Ten-year follow-up of the UK START A and B trials of hypofractionated breast radiotherapy. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Lancet Oncol. 2013;14(11):1086–1094

Year

2013

Version

Pending verification

Disease sites

Breast

Fractionation context

Hypofractionated vs 50 Gy/25 fx

Last reviewed by DoseLab

Pending verification

Review of normal tissue tolerance data by Emami, updating the 1991 tolerance tables with more recent clinical evidence. Citation as given in the compiling protocol's reference list; not yet checked by DoseLab.

Publication / protocol

Reports of Radiotherapy and Oncology. 2013;1(1):35–48

Year

2013

Version

Pending verification

Disease sites

Head & Neck, CNS / Brain

Fractionation context

Conventional fractionation

Last reviewed by DoseLab

Pending verification

RTOG 0418, a phase II study of post-operative pelvic IMRT for endometrial cancer, which tested whether IMRT could be delivered across many centers and tracked bowel toxicity. Citation checked against Europe PMC.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2012;84(1):e23–e28

Year

2012

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

American Brachytherapy Society consensus on vaginal cuff brachytherapy after hysterectomy: indications, applicators, prescription point (surface or 5 mm depth), treatment length and common HDR and LDR schedules. Citation checked against Europe PMC.

Publication / protocol

Brachytherapy. 2012;11(1):58–67

Year

2012

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

American Brachytherapy Society consensus on locally advanced cervical cancer — general principles: applicator choice, imaging, treatment time, dose reporting and the move from point A to volume-based planning. Citation checked against Europe PMC.

Publication / protocol

Brachytherapy. 2012;11(1):33–46

Year

2012

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

American Brachytherapy Society consensus on high-dose-rate brachytherapy for cervical cancer: HDR fractionation, combining EBRT and HDR doses in EQD2, and organ dose reporting. Citation checked against Europe PMC.

Publication / protocol

Brachytherapy. 2012;11(1):47–52

Year

2012

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Consensus contouring atlas and IMRT planning guidelines for anal cancer from the Australasian Gastrointestinal Trials Group, covering gross tumor, elective nodal volumes and organs at risk. Citation checked against Europe PMC.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2012;83(5):1455–1462

Year

2012

Version

Pending verification

Disease sites

GI

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

NRG Oncology's hosted copy of the RTOG female normal pelvis atlas (from the RTOG pelvic normal tissue consensus): bladder, rectum, sigmoid, bowel, femoral heads and other pelvic organs, as a PowerPoint and an interactive viewer.

Publication / protocol

NRG Oncology CIRO contouring atlas

Year

2012

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Retrospective study of 99 plans comparing five homogeneity index formulas. Its introduction summarizes the RTOG index (maximum isodose in the target ÷ reference isodose), D5%/D95%, and (D2% − D98%) ÷ prescribed dose, and explains that D2% and D98% are used because true point maximum and minimum doses are sensitive to calculation grid size and placement. Full text read in Europe PMC (PMC3532749).

Publication / protocol

J Med Phys. 2012;37(4):207–213

Year

2012

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-03

Prospective GORTEC study of IMRT for head and neck cancer, reporting dosimetry, xerostomia and control. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiother Oncol. 2012;103(1):57–62

Year

2012

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Prospective trial of prostate SBRT for low-risk disease with long-term follow-up. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2012;82(2):877–882

Year

2012

Version

Pending verification

Disease sites

Prostate

Fractionation context

SBRT, 5 fractions

Last reviewed by DoseLab

Pending verification

RTOG consensus panel atlas of male and female pelvic normal tissues. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2012;83(3):e353–e362

Year

2012

Version

Pending verification

Disease sites

Prostate, GI, GYN, GU

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Phase 3 CROSS trial: weekly carboplatin and paclitaxel with 41.4 Gy in 23 fractions before surgery improved survival over surgery alone for esophageal and junctional cancer. Citation checked against Europe PMC.

Publication / protocol

N Engl J Med. 2012;366(22):2074–2084

Year

2012

Version

Pending verification

Disease sites

GI

Fractionation context

41.4 Gy / 23 fx

Last reviewed by DoseLab

Pending verification

GEC-ESTRO gynecological recommendations on MRI for image-guided cervix brachytherapy: field strength, T2-weighted sequences and the para-axial, para-sagittal and para-coronal planes oriented to the applicator. Open access. Citation checked against Europe PMC.

Publication / protocol

Radiother Oncol. 2012;103(1):113–122

Year

2012

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

AAPM task group report on biologically based treatment planning. It describes the common models — the Poisson TCP model, empirical sigmoid TCP models defined by D50 and a normalized dose-response gradient, and the Lyman-Kutcher-Burman NTCP model with parameters TD50, m and n — defines serial and parallel organs and the volume effect, and advises using the LQ-equivalent dose in 2 Gy fractions rather than physical dose in TCP and NTCP calculations. Its recommendations: plan evaluation should at present be based on established dose-volume criteria; relative TCP/NTCP estimates may help choose between rival plans if users understand the models and parameters in their planning system; absolute TCP/NTCP estimates are not warranted as the main indicators of plan quality; and review of the 3D dose distribution should always remain part of plan evaluation. Read in the AAPM report PDF (Report No. 166, March 2012).

Publication / protocol

Med Phys. 2012;39(3):1386–1409 (AAPM Report No. 166)

Year

2012

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-07

International consensus guidelines for the clinical target volumes in IMRT for the definitive treatment of cervical cancer, drawn mainly on MRI: the gross tumor, cervix, uterus, parametria, vagina and nodal regions. Citation checked against Europe PMC.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2011;79(2):348–355

Year

2011

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

A thoracic organ-at-risk contouring atlas with discussion of dose limits, covering the lung, proximal bronchial tree, esophagus, spinal cord, ribs and brachial plexus. A published letter in response discusses esophageal delineation.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2011;81(5):1442–1457

Year

2011

Version

Pending verification

Disease sites

Lung, Breast, GI

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

CT-based guidelines for delineating the organs at risk involved in swallowing. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiother Oncol. 2011;101(3):394–402

Year

2011

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Atlas for contouring the heart and its substructures, including the coronary arteries, developed and validated for studying cardiac dose in breast radiotherapy.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2011;79(1):10–18

Year

2011

Version

Pending verification

Disease sites

Breast, GI

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Review by the originator of the term biologically effective dose (BED, introduced in Br J Radiol in 1989). Gives the BED formula — nd[1 + d/(α/β)], with an optional overall-time term — and the conversion to the equivalent dose in 2 Gy fractions by dividing BED by 1 + 2/(α/β) (1.2 for α/β = 10 Gy, 1.67 for 3 Gy, 2.0 for 2 Gy). Its worked example: 30 × 2 Gy = 60 Gy is 72 Gy10 to early-responding tissue and 100 Gy3 to late-responding tissue, but 60 Gy EQD2 to both. Full text read in Europe PMC (PMC3473681).

Publication / protocol

Br J Radiol. 2010;83(991):554–568

Year

2010

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-06

Thirty-seven patients given definitive chemoradiation for esophageal cancer. All lung dose–volume parameters studied, including the mean lung dose, were associated with symptomatic pneumonitis. Citation checked against Europe PMC; DoseLab has read only the abstract.

Publication / protocol

Radiother Oncol. 2010;95(2):240–244

Year

2010

Version

Pending verification

Disease sites

GI

Fractionation context

60 Gy / 30 fx

Last reviewed by DoseLab

Pending verification

Sixty patients treated with 3–5 fraction SBRT for peripheral lung lesions. The chest wall volume receiving 30 Gy best predicted severe pain or rib fracture; the authors advise limiting it to under 30 cm³ where possible without compromising coverage. DoseLab read the abstract.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;76(3):796–801

Year

2010

Version

Pending verification

Disease sites

Lung, GI

Fractionation context

SBRT, 3–5 fx

Last reviewed by DoseLab

2026-09-29

RTOG consensus guidelines for the post-prostatectomy clinical target volume.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;76(2):361–368

Year

2010

Version

Pending verification

Disease sites

Prostate

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

A planning paper describing how to contour the hippocampus, build the avoidance region and plan hippocampal-sparing whole-brain radiotherapy with helical tomotherapy and linac-based IMRT, 30 Gy in 10 fractions. Citation checked against Crossref.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;78(4):1244–1252

Year

2010

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

30 Gy / 10 fx

Last reviewed by DoseLab

Pending verification

ICRU report on prescribing, recording and reporting intensity-modulated photon therapy. DoseLab has not read the report itself (it is sold by the ICRU). Its homogeneity index, (D2% − D98%) / D50%, is checked as quoted in the open-access Yan 2019 paper.

Publication / protocol

J ICRU. 2010;10(1):1–107

Year

2010

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Ten-year results of the Ontario Clinical Oncology Group randomized trial comparing 42.5 Gy in 16 fractions with 50 Gy in 25 fractions of whole-breast irradiation after breast-conserving surgery, without a boost. Many clinics prescribe the schedule as 42.56 Gy (2.66 Gy × 16). Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

N Engl J Med. 2010;362(6):513–520

Year

2010

Version

Pending verification

Disease sites

Breast

Fractionation context

42.5 Gy/16 fx vs 50 Gy/25 fx

Last reviewed by DoseLab

Pending verification

A 2010 journal supplement summarizing dose-volume and outcome data for normal tissues, organized by organ.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S1–S160

Year

2010

Version

Pending verification

Disease sites

Lung, Prostate, GI, Head & Neck, CNS / Brain, Breast

Fractionation context

Primarily conventional fractionation

Last reviewed by DoseLab

Pending verification

The brainstem chapter of the 2010 QUANTEC supplement, reviewing dose–volume data for brainstem injury. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S36–S41

Year

2010

Version

Pending verification

Disease sites

Head & Neck, CNS / Brain

Fractionation context

Conventional fractionation

Last reviewed by DoseLab

Pending verification

The esophagus chapter of the 2010 QUANTEC supplement, reviewing dose–volume parameters reported to correlate with esophageal toxicity and the difficulty of isolating any single one.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S86–S93

Year

2010

Version

Pending verification

Disease sites

Lung, GI

Fractionation context

Primarily conventional fractionation

Last reviewed by DoseLab

Pending verification

The heart chapter of the 2010 QUANTEC supplement, covering pericarditis and long-term cardiac effects and the dose–volume relationships reported for them. A later letter in the same journal comments on its breast-cancer conclusions.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S77–S85

Year

2010

Version

Pending verification

Disease sites

Lung, Breast, Other, GI

Fractionation context

Primarily conventional fractionation

Last reviewed by DoseLab

Pending verification

The lung chapter of the 2010 QUANTEC supplement. It reviews the relationship between lung dose–volume parameters and radiation pneumonitis and emphasizes that no single threshold cleanly separates safe from unsafe plans.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S70–S76

Year

2010

Version

Pending verification

Disease sites

Lung, Breast, GI

Fractionation context

Primarily conventional fractionation

Last reviewed by DoseLab

Pending verification

The spinal cord chapter of the 2010 QUANTEC supplement. It reviews the clinical and experimental data on radiation myelopathy, the estimated risk at given dose levels, and the limitations of the evidence.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S42–S49

Year

2010

Version

Pending verification

Disease sites

Lung, Head & Neck, GI, Other, CNS / Brain

Fractionation context

Conventional fractionation, with a section on hypofractionated / SRS data

Last reviewed by DoseLab

Pending verification

The optic nerve and chiasm chapter of the 2010 QUANTEC supplement. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S28–S35

Year

2010

Version

Pending verification

Disease sites

Head & Neck, CNS / Brain

Fractionation context

Conventional fractionation

Last reviewed by DoseLab

Pending verification

The hearing-loss chapter of the 2010 QUANTEC supplement. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S50–S57

Year

2010

Version

Pending verification

Disease sites

Head & Neck, CNS / Brain

Fractionation context

Conventional fractionation

Last reviewed by DoseLab

Pending verification

Phase 2 RTOG trial of preoperative IMRT with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment was 45 Gy in 25 fractions with IMRT to the pelvis, then a 3D conformal boost of 5.4 Gy in 3 fractions. Section 6.5 lists the IMRT planning constraints for small bowel (absolute volumes), femoral heads and bladder, and section 6.7 the variation-acceptable levels. DoseLab read sections 6.1–6.7 of the IROC Houston copy (version date 17 April 2008, update 30 March 2010). The trial results were published by Hong et al. in 2015.

Publication / protocol

Protocol document, RTOG 0822

Year

2010

Version

Version date 17 April 2008; update date 30 March 2010

Disease sites

GI

Fractionation context

45 Gy / 25 fx IMRT + 5.4 Gy / 3 fx 3D boost (50.4 Gy / 28 fx)

Last reviewed by DoseLab

2026-09-29

Phase 2 multicenter trial of SBRT for medically inoperable, early-stage, peripheral non-small cell lung cancer. The original normal-tissue limits written for this trial are reproduced and discussed in Timmerman 2022 (Table 1).

Publication / protocol

JAMA. 2010;303(11):1070–1076

Year

2010

Version

Pending verification

Disease sites

Lung

Fractionation context

SBRT (3 fractions)

Last reviewed by DoseLab

Pending verification

AAPM task group report describing best-practice guidelines for stereotactic body radiation therapy, including a table of normal-tissue dose constraints. Bibliographic details confirmed against the journal index; table map not yet checked.

Publication / protocol

Med Phys. 2010;37(8):4078–4101

Year

2010

Version

Pending verification

Disease sites

Lung, Other

Fractionation context

SBRT (1–5 fractions)

Last reviewed by DoseLab

Pending verification

The QUANTEC overview paper, whose summary table gathers the approximate dose/volume/outcome data from each organ chapter. Its footnotes stress that the data are estimates from the literature, should be applied with caution, and largely do not reflect modern IMRT. DoseLab read the esophagus row (mean dose <34 Gy for grade ≥3 acute esophagitis, 5–20%, 3D-CRT) from the open-access manuscript, and the lung, heart, liver, kidney, stomach and small bowel rows used on the GI pages from the journal's full-text table.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–S19

Year

2010

Version

Pending verification

Disease sites

Lung, Prostate, GI, Head & Neck, CNS / Brain, Breast

Fractionation context

Standard fractionation (1.8–2.0 Gy per fraction) unless noted

Last reviewed by DoseLab

2026-09-29

PORTEC-2 randomized women with high-intermediate risk endometrial cancer to vaginal brachytherapy or pelvic external beam radiotherapy after surgery. Vaginal brachytherapy gave similar vaginal control with fewer bowel side effects. Citation checked against Europe PMC.

Publication / protocol

Lancet. 2010;375(9717):816–823

Year

2010

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

RTOG consensus atlas of the elective clinical target volumes for anal and rectal cancer, hosted by NRG Oncology alongside its GI protocol templates. Citation checked against Europe PMC.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2009;74(3):824–830

Year

2009

Version

Pending verification

Disease sites

GI

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Individual-patient-data meta-analysis of chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Radiother Oncol. 2009;92(1):4–14

Year

2009

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Describes and validates a standardized CT-based method for delineating the brachial plexus, developed in patients treated with IMRT for head and neck cancer.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2008;72(5):1362–1367

Year

2008

Version

Pending verification

Disease sites

Head & Neck, Lung

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Study of submandibular gland salivary flow after head and neck radiotherapy in relation to gland dose. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2008;72(2):373–382

Year

2008

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Defines the gradient index (GI) as the ratio of the volume of half the prescription isodose to the volume of the prescription isodose — for a plan normalized to the 50% isodose line, the 25% isodose volume over the 50% isodose volume. The authors use it to compare plans of equal conformity, to explore prescription isodoses and to compare treatment modalities. Definition read in the abstract (Europe PMC); citation checked against Crossref.

Publication / protocol

J Neurosurg. 2006;105 Suppl:194–201

Year

2006

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

Single fraction (radiosurgery)

Last reviewed by DoseLab

2026-10-03

Critical review of the conformity indices described in the literature and their fields of application. Citation and abstract checked in Europe PMC and Crossref; full text not read.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2006;64(2):333–342

Year

2006

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

The second GEC-ESTRO gynecological recommendations: the dose–volume parameters for image-based cervix brachytherapy (D90 and D100 for the targets, D2cc and D0.1cc for the organs) and how to report them, with notes on radiobiology and EQD2. Citation checked against Europe PMC.

Publication / protocol

Radiother Oncol. 2006;78(1):67–77

Year

2006

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Analysis of dosimetric risk factors for acute esophagitis with concurrent chemoradiation. Citation as given in the eviQ reference list; not yet checked against the journal.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2006;66(1):100–107

Year

2006

Version

Pending verification

Disease sites

Lung

Fractionation context

Conventional chemoradiation

Last reviewed by DoseLab

Pending verification

NRG Oncology's page for RTOG 0615, a phase 2 trial of concurrent chemoradiotherapy with IMRT (or 3D-CRT) plus bevacizumab for locally or regionally advanced nasopharyngeal cancer. The protocol document lists planning goals for head and neck organs. The larynx and cochlea values in DoseLab's head and neck table are credited to it in the compiling protocol; DoseLab could not extract readable text from the protocol copy it found, so these values have not yet been checked against the protocol itself.

Publication / protocol

Protocol document, RTOG 0615

Year

2006

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Conventional fractionation with concurrent chemotherapy

Last reviewed by DoseLab

Pending verification

AAPM task group report on respiratory motion in thoracic, abdominal and pelvic treatment. It groups management approaches into motion-encompassing methods, respiratory gating, breath-hold techniques, forced shallow breathing (such as abdominal compression) and respiration-synchronized (tracking) techniques. Read in the AAPM report PDF (Report No. 91, July 2006): using ICRU Report 62 nomenclature, the PTV adds margins to the CTV for respiratory (intrafraction) motion, interfraction motion and set-up error; without a respiratory management device the entire range of motion should be considered in the internal margin; and for lung tumors a maximum intensity projection (MIP) can give the motion-encompassing volume, provided there is no mediastinal involvement.

Publication / protocol

Med Phys. 2006;33(10):3874–3900

Year

2006

Version

Pending verification

Disease sites

Lung, GI, Breast

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-06

Planning study comparing 3D conformal techniques for postoperative gastric cancer radiotherapy. Cited, with the CROSS trial, for a heart limit in upper GI protocols. Citation checked against Europe PMC; DoseLab has not read the paper.

Publication / protocol

Radiother Oncol. 2005;74(3):301–306

Year

2005

Version

Pending verification

Disease sites

GI

Fractionation context

Conventional

Last reviewed by DoseLab

Pending verification

Comparative analysis of the EORTC 22931 and RTOG 9501 post-operative chemoradiation trials. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Head Neck. 2005;27(10):843–850

Year

2005

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Phase 3 trial showing that temozolomide given with and after radiotherapy (60 Gy in 30 fractions) improved survival in glioblastoma compared with radiotherapy alone. Citation checked against Crossref.

Publication / protocol

N Engl J Med. 2005;352(10):987–996

Year

2005

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

60 Gy / 30 fx

Last reviewed by DoseLab

Pending verification

The first GEC-ESTRO gynecological working group recommendations, which defined the image-based brachytherapy volumes used today — GTV, high-risk CTV and intermediate-risk CTV — with emphasis on MRI. Citation checked against Europe PMC.

Publication / protocol

Radiother Oncol. 2005;74(3):235–245

Year

2005

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Review of the ICRU target-volume concepts. It summarizes ICRU Report 62's internal margin (for variations in the size, shape and position of the CTV, for example from organ filling or respiration) and set-up margin, and its planning organ at risk volume (PRV): a margin around an organ at risk, analogous to the PTV margin, because systematic and random errors apply to organs at risk as much as to the CTV. It notes that a PRV substantially enlarges the organ and may create dilemmas with target dose, so it is needed only in certain circumstances — around organs whose damage is especially dangerous, such as the spinal cord, a "serial" tissue. Full text read in Europe PMC (PMC1434601).

Publication / protocol

Cancer Imaging. 2004;4(2):153–161

Year

2004

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-06

RTOG/Intergroup phase 3 trial of post-operative radiotherapy with or without concurrent cisplatin. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

N Engl J Med. 2004;350(19):1937–1944

Year

2004

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

EORTC phase 3 trial of post-operative radiotherapy with or without concurrent cisplatin. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

N Engl J Med. 2004;350(19):1945–1952

Year

2004

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Randomized trial of five versus six fractions per week of conventionally fractionated radiotherapy for head and neck squamous cell carcinoma. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Lancet. 2003;362(9388):933–940

Year

2003

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

2 Gy fractions, 5 vs 6 fractions per week

Last reviewed by DoseLab

Pending verification

Intergroup phase 3 trial comparing 64.8 Gy with 50.4 Gy, both with cisplatin and 5-FU, for definitive treatment of esophageal cancer. The higher dose did not improve survival or local control, so 50.4 Gy became the standard. Citation checked against Europe PMC.

Publication / protocol

J Clin Oncol. 2002;20(5):1167–1174

Year

2002

Version

Pending verification

Disease sites

GI

Fractionation context

50.4 Gy / 28 fx vs 64.8 Gy / 36 fx

Last reviewed by DoseLab

Pending verification

Technical note reviewing earlier radiosurgery conformity measures, showing that they can give false perfect scores, and deriving a new index that does not. The abstract was read in Europe PMC; the index's formula is checked as described in Menon 2018. Citation checked against Crossref.

Publication / protocol

J Neurosurg. 2000;93 Suppl 3:219–222

Year

2000

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

Single fraction (radiosurgery)

Last reviewed by DoseLab

Pending verification

RTOG 90-05 dose-escalation study of single-fraction radiosurgery for previously irradiated brain tumors and metastases. It defined the maximum tolerated single dose by tumor diameter — 24 Gy up to 20 mm, 18 Gy for 21–30 mm and 15 Gy for 31–40 mm — which still shapes size-based SRS dose selection. Citation checked against Crossref.

Publication / protocol

Int J Radiat Oncol Biol Phys. 2000;47(2):291–298

Year

2000

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

Single fraction

Last reviewed by DoseLab

Pending verification

GOG 120 showed that cisplatin-based chemotherapy given with radiation improved survival in locally advanced cervical cancer — one of the trials behind weekly cisplatin chemoradiation. Citation checked against Europe PMC.

Publication / protocol

N Engl J Med. 1999;340(15):1144–1153

Year

1999

Version

Pending verification

Disease sites

GYN

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Measurement of salivary flow from each parotid gland before and after conformal and intensity-modulated head and neck radiotherapy, related to gland dose. Citation checked against Crossref; content not yet reviewed by DoseLab.

Publication / protocol

Int J Radiat Oncol Biol Phys. 1999;45(3):577–587

Year

1999

Version

Pending verification

Disease sites

Head & Neck

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

ICRU supplement to Report 50 that refined the PTV concept: an internal margin for variations in the CTV's size, shape and position, a set-up margin for planning and positioning uncertainties, and a planning organ at risk volume (PRV) around organs at risk. DoseLab has not read the report itself (it is sold by the ICRU); these points are checked as summarized in the open-access Burnet 2004 review. Citation as given in the DEGRO/DGMP statement on ICRU Report 91 (Wilke 2019).

Publication / protocol

J ICRU. 1999;32(1):1–52

Year

1999

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

RTOG task-force guidelines for radiosurgery quality assurance, setting out a standard data set and minor and major protocol deviations. The paper itself is paywalled; DoseLab checked its conformity, coverage and homogeneity definitions as quoted in Kataria 2012 and Menon 2018. Citation checked against Crossref.

Publication / protocol

Int J Radiat Oncol Biol Phys. 1993;27(5):1231–1239

Year

1993

Version

Pending verification

Disease sites

CNS / Brain

Fractionation context

Single fraction (radiosurgery)

Last reviewed by DoseLab

Pending verification

Describes the cumulative dose-volume histogram as a graphical summary of the dose within a volume of interest, useful for comparing rival plans, and warns that because positional information is lost it should not be the sole criterion for plan evaluation. Abstract read in Europe PMC; citation checked against Crossref.

Publication / protocol

Int J Radiat Oncol Biol Phys. 1991;21(1):71–78

Year

1991

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

2026-10-06

The short paper that extended Withers' four Rs of radiotherapy to five by adding intrinsic radiosensitivity. Citation checked in Europe PMC; DoseLab has not read the paper itself and describes it as summarized by Brown and colleagues (2014).

Publication / protocol

Int J Radiat Biol. 1989;56(6):1045–1048

Year

1989

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

The 1989 review that proposed the term biologically effective dose, based on the linear-quadratic model, with an overall-time factor. Citation checked in Europe PMC; DoseLab has read the author's 2010 follow-up review rather than this paper.

Publication / protocol

Br J Radiol. 1989;62(740):679–694

Year

1989

Version

Pending verification

Disease sites

Pending verification

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

NRG Oncology's breast downloads page, which links the RTOG Breast Cancer Atlas for Radiation Therapy Planning, an NRG whole-breast radiation therapy template and the RADCOMP breast atlas.

Publication / protocol

Pending verification

Year

Pending verification

Version

Pending verification

Disease sites

Breast

Fractionation context

Pending verification

Last reviewed by DoseLab

Pending verification

Online collection of evidence-based cancer treatment protocols, including radiation oncology protocols.

Publication / protocol

Online resource

Year

Pending verification

Version

Pending verification

Disease sites

Lung, Prostate, GI, Head & Neck, Breast, CNS / Brain, GYN, GU

Fractionation context

Various

Last reviewed by DoseLab

Pending verification

NRG Oncology's protocol table, covering current and closed RTOG/NRG trials. A protocol's own constraint table is written for that protocol's fractionation, target definitions and contouring instructions — the numbers do not transfer to another schedule. Individual protocols are added to DoseLab as separate entries, each with its version.

Publication / protocol

Pending verification

Year

Pending verification

Version

Pending verification

Disease sites

Lung, Prostate, GI, Head & Neck, Breast, CNS / Brain, GYN, GU

Fractionation context

Protocol-specific

Last reviewed by DoseLab

Pending verification

NRG Oncology's protocol page for NSABP B-51 / RTOG 1304, a phase 3 trial of regional nodal irradiation after neoadjuvant chemotherapy. The protocol document holds the trial's normal-tissue requirements.

Publication / protocol

Protocol document, NSABP B-51

Year

Pending verification

Version

Pending verification

Disease sites

Breast

Fractionation context

Conventional fractionation, chest wall/breast and regional nodes

Last reviewed by DoseLab

Pending verification

NRG Oncology's protocol page for RTOG 0813, with the protocol document and supporting forms. Read the trial's own dose constraints, its definition of a central tumor and its plan-evaluation requirements in the protocol document. Results are published separately as the RTOG 0813 trial report.

Publication / protocol

Protocol document, RTOG 0813

Year

Pending verification

Version

Version dated 2015-06-08 (per the NRG protocol page)

Disease sites

Lung

Fractionation context

SBRT, 5 fractions

Last reviewed by DoseLab

Pending verification

NRG Oncology's protocol page for RTOG 0915, linking the protocol PDF. Read the trial's normal-tissue constraints and its conformity and dose-falloff requirements in the protocol document. Results are published separately as the RTOG 0915 trial report.

Publication / protocol

Protocol document, RTOG 0915 (NCCTG N0927)

Year

Pending verification

Version

Version dated 2014-03-06 (per the NRG protocol page)

Disease sites

Lung

Fractionation context

SBRT, 1 and 4 fractions

Last reviewed by DoseLab

Pending verification

NRG Oncology's page for RTOG 0924, a phase 3 trial of androgen deprivation and high-dose radiotherapy with or without whole-pelvic radiotherapy.

Publication / protocol

Protocol, RTOG 0924

Year

Pending verification

Version

Pending verification

Disease sites

Prostate

Fractionation context

Conventional (prostate and pelvic nodes)

Last reviewed by DoseLab

Pending verification